Commissies

Visitatie Registratie Commissie (VRC)

Binnen de NVCG is de Visitatie Registratie Commissie ingesteld met als primaire doelstelling het onderzoeken, visiteren en registreren van artsen (zowel leden als niet-leden van de NVCG) voor het verkrijgen van een NVCG-certificaat. Op grond van artikel D.1. lid 1 van het Besluit Cosmetische Geneeskunde kunnen alleen cosmetisch artsen die zijn ingeschreven in het (niet-openbare) register van de NVCG in aanmerking komen voor de profielerkenning cosmetisch arts KNMG.
Tevens is de Visitatie Registratie Commissie verantwoordelijk voor het opstellen en bewaken van het accreditatiebeleid van de NVCG.
 

De leden van de Visitatie Registratie Commissie zijn:

dr. Pieter Siebenga (voorzitter)
drs. Pascal Meijer

drs. Branka Martijn

Onderwijscommissie (OC)

De Onderwijscommissie is één van de belangrijkste commissies van de NVCG. Vanuit de  onderwijscommissie wordt gewerkt aan het theoretisch-wetenschappelijk gedeelte van het onderwijs voor de profielopleiding Cosmetische geneeskunde. Het theoretisch onderwijs is verdeeld in diverse modules en wordt ingevuld door diverse nationale en internationale specialisten op het terrein van de verschillende deelgebieden die in de modules aan bod komen.
 

De leden van de Onderwijscommissie zijn:

drs. Leanne Wong (voorzitter)
dr. Tom Decates
drs. Maarten Façee Schaeffer
drs. Jeanette Hessels
drs. Robert Boonen 
drs. Maartje de Bie
drs. Vivian Beekman
drs. Awat Hassan 

Product- en Complicatie Registratie Commissie (PCR)

De Product- en Complicatie Registratie Commissie (PCR) houdt zich bezig met het registreren van complicaties die zich voordoen in het werkgebied van de cosmetisch arts. Door het landelijk registreren van de complicaties die zich voordoen in “het veld” zal lering kunnen worden getrokken zodat onveilige producten of behandeltechnieken tijdig ontdekt kunnen worden en de nodige acties in gang kunnen worden gezet. Zo heeft de PCR in het verleden een onveilig middel ontdekt via de registraties die werden gedaan. In samenwerking met de Inspectie Gezondheidszorg en Jeugd (IGJ) heeft de PCR ervoor gezorgd dat het middel van de markt is gehaald en heeft zo een hoop leed onder de bevolking voorkomen. De PCR houdt voorafgaand aan elke Algemene Ledenvergaderingen van de NVCG een uur een complicatiebespreking. Hier worden recente complicaties gepresenteerd en besproken door de leden en toehoorders. De PCR heeft het initiatief genomen een database voor complicaties te creëren die via een online registratieformulier door de leden en toehoorders kunnen worden aangevuld. 

De leden van de Product- en Complicatie Registratie Commissie zijn:

dr. Tom Decates (voorzitter)
dr. Jani van Loghem
dr. Leonie Schelke

Redactie Cg Magazine

 De leden van de Redactie Cg Magazine Commissie zijn:

drs. Pascal Meijer (hoofdredacteur)
drs. Carina Domingues
drs. Tatjana Water
drs. Muriëlle van Engelen 
drs. Nastja Hendriks 
Ank de Bruin

 

Domeingroep Chirurgie 

 De leden van de Domeingroep Chirurgie Commissie zijn:

drs. Robert Boonen (voorzitter)
dr. Thanya Tha-In

 

Commissie Wetenschap

In het licht van de huidige maatschappelijke onrust rondom ons prachtige vak, is het heel erg belangrijk dat we onze behandelingen kunnen stoelen op gedegen wetenschappelijk onderzoek. In dat kader zijn deze lijsten met artikelen verzameld, opdat onze patiënten nog beter voorgelicht kunnen worden. Bovendien vormt dit mede de basis voor de gepubliceerde behandel richtlijnen.
 

De leden van de Commissie Wetenschap zijn:

drs. Serge Steenen (voorzitter)
dr. Janneke van Rijswijk-Gilden
drs. Aarent Brand
 

 

Kascommissie

Onafhankelijke commissie die de boekhouding van onze vereniging controleert. De belangrijkste taak is het controleren van de jaarrekening.

 Leden kascommissie:
Drs. Rick Dassen
Drs. Griet Snick

Databases

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Botulinum toxin
  1. Zarone, F., et al., Treatment Concept for a Patient with a High Smile Line and Gingival Pigmentation: A Case Report. Int J Periodontics Restorative Dent, 2017. 37(2): p. e142-e148.
  2. Wollina, U. and A. Goldman, Botulinum toxin A and/or soft tissue fillers for facial rehabilitation. Wien Med Wochenschr, 2017. 167(3-4): p. 92-95.
  3. Szuch, E., et al., Head drop after botox: Electrodiagnostic evaluation of iatrogenic botulinum toxicity. Clin Neurol Neurosurg, 2017. 156: p. 1-3.
  4. Sapra, P., et al., A Single-blind, Split-face, Randomized, Pilot Study Comparing the Effects of Intradermal and Intramuscular Injection of Two Commercially Available Botulinum Toxin A Formulas to Reduce Signs of Facial Aging. J Clin Aesthet Dermatol, 2017. 10(2): p. 34-44.
  5. Prager, W., D. Nogueira Teixeira, and P.S. Leventhal, IncobotulinumtoxinA for Aesthetic Indications: A Systematic Review of Prospective Comparative Trials. Dermatol Surg, 2017.
  6. Pelle-Ceravolo, M. and M. Angelini, Transcutaneous Brow Shaping: A Straightforward and Precise Method to Lift and Shape the Eyebrows. Aesthet Surg J, 2017.
  7. Ma, F., et al., Ultrastructural changes in human masseter muscles after botulinum neurotoxin a injection. Muscle Nerve, 2017.
  8. Kim, N.H., et al., A Simplified Approach to Botulinum Toxin Injection for the Lower Face: Concept of a 24-Hour Clock. Plast Reconstr Surg, 2017. 139(3): p. 816e-818e.
  9. Kaplan, J.B., Consideration of Muscle Depth for Botulinum Toxin Injections: A Three-Dimensional Approach. Plast Surg Nurs, 2017. 37(1): p. 32-38.
  10. Jiang, H., J. Zhou, and S. Chen, Different Glabellar Contraction Patterns in Chinese and Efficacy of Botulinum Toxin Type A for Treating Glabellar Lines: A Pilot Study. Dermatol Surg, 2017.
  11. Hur, M.S., Anatomical relationships of the procerus with the nasal ala and the nasal muscles: transverse part of the nasalis and levator labii superioris alaeque nasi. Surg Radiol Anat, 2017.
  12. Franca, K., et al., The history of Botulinum toxin: from poison to beauty. Wien Med Wochenschr, 2017.
  13. Fouche, J.J., et al., Left/Right Pain Asymmetry With Injectable Cosmetic Treatments for the Face. Aesthet Surg J, 2017.
  14. De la Torre Canales, G., et al., Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. Clin Oral Investig, 2017. 21(3): p. 727-734.
  15. Consideration of Muscle Depth for Botulinum Toxin Injections: A Three-Dimensional Approach. Plast Surg Nurs, 2017. 37(1): p. E2.
  16. Zhu, J., et al., The Efficacy and Safety of Fractional CO2 Laser Combined with Topical Type A Botulinum Toxin for Facial Rejuvenation: A Randomized Controlled Split-Face Study. Biomed Res Int, 2016. 2016: p. 3853754.
  17. Westbrook, A.D., A Practical Guide to Botulinum Toxin Procedures. Fam Med, 2016. 48(3): p. 234-5.
  18. Vanaman, M.M.D., S.G.M.D.F.F. Fabi, and S.E.M.D. Cox, Neck Rejuvenation Using a Combination Approach: Our Experience and a Review of the Literature. Dermatologic Surgery, 2016. 42 Supplement(2): p. S94-S100.
  19. Sundaram, H., et al., Global Aesthetics Consensus: Botulinum Toxin Type A–Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg, 2016. 137(3): p. 518e-529e.
  20. Sundaram, H., et al., Global Aesthetics Consensus: Botulinum Toxin Type A-Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg, 2016. 137(3): p. 518e-29e.
  21. Sundaram, H., et al., Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A-Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations. Plast Reconstr Surg, 2016. 137(5): p. 1410-23.
  22. Sundaram, H., et al., Aesthetic Applications of Botulinum Toxin A in Asians: An International, Multidisciplinary, Pan-Asian Consensus. Plast Reconstr Surg Glob Open, 2016. 4(12): p. e872.
  23. Singh, S., S. Kaur, and P. Wilson, Plantar hyperhidrosis: A review of current management. J Dermatolog Treat, 2016: p. 1-6.
  24. Scherer, M.A., Specific aspects of a combined approach to male face correction: botulinum toxin A and volumetric fillers. J Cosmet Dermatol, 2016. 15(4): p. 566-574.
  25. Scaglione, F., Conversion Ratio between Botox((R)), Dysport((R)), and Xeomin((R)) in Clinical Practice. Toxins (Basel), 2016. 8(3).
  26. Narurkar, V.A.M.D., et al., A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study. Dermatologic Surgery, 2016. 42 Supplement(2): p. S177-S191.
  27. Nair, K.P., Review of Manual of Botulinum Toxin Therapy, 2nd ed. JAMA Neurol, 2016. 73(3): p. 359.
  28. Min, P., et al., Alteration of Skin Mechanical Properties in Patients Undergoing Botulinum Toxin Type A Injections of Forehead Rhytides. Aesthetic Plast Surg, 2016.
  29. Mahmoud, B.H., et al., Prospective Randomized Split-Face Comparative Study Between Topical Botulinum Toxin A Surface Application and Local Injection for Crow’s Feet. Dermatol Surg, 2016. 42(4): p. 554-6.
  30. Lee, S.-K.M.D.P. and H.S.M.D.P. Kim, Asymmetry and Maldistribution of Polyacrylamide Hydrogel Filler in the Infraorbital Area Successfully Managed With Botulinum Toxin A Treatment. Dermatologic Surgery, 2016. 42(12): p. 1395-1397.
  31. Lee, M.J., et al., Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study. J Neurol Sci, 2016. 363: p. 51-4.
  32. Langelier, N.M.D., K.M.D. Beleznay, and J.M.D. Woodward, Rejuvenation of the Upper Face and Periocular Region: Combining Neuromodulator, Facial Filler, Laser, Light, and Energy-Based Therapies for Optimal Results. Dermatologic Surgery, 2016. 42 Supplement(2): p. S77-S82.
  33. Kuwahara, H. and R. Ogawa, Using a Vibration Device to Ease Pain During Facial Needling and Injection. Eplasty, 2016. 16: p. e9.
  34. Kucuker, I., et al., The Effect of Chemodenervation by Botulinum Neurotoxin on the Degradation of Hyaluronic Acid Fillers: An Experimental Study. Plast Reconstr Surg, 2016. 137(1): p. 109-13.
  35. Kollewe, K., et al., Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm (Vienna), 2016.
  36. Kaplan, J.B., The Dilution Confusion: Easy Dosing for Botulinum Toxins. Plast Surg Nurs, 2016. 36(1): p. 24-7.
  37. Hwang, C.J., Periorbital Injectables: Understanding and Avoiding Complications. J Cutan Aesthet Surg, 2016. 9(2): p. 73-9.
  38. Humphrey, S.M.D.F.F., K.M.D.F.F. Beleznay, and R.M.D.F.F. Fitzgerald, Combination Therapy in Midfacial Rejuvenation. Dermatologic Surgery, 2016. 42 Supplement(2): p. S83-S88.
  39. Gupta, A.K.M.D.P.F. and J.P. Carviel, A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia. Dermatologic Surgery, 2016. 42(12): p. 1335-1339.
  40. Fraint, A., P. Vittal, and C. Comella, Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe? Ther Clin Risk Manag, 2016. 12: p. 147-54.
  41. Fabi, S.G.M.D., et al., Combining Microfocused Ultrasound With Botulinum Toxin and Temporary and Semi-Permanent Dermal Fillers: Safety and Current Use. Dermatologic Surgery, 2016. 42 Supplement(2): p. S168-S176.
  42. Fabi, S.G.M.D. and J.M.D. Carruthers, Single Modality Approach to Rejuvenate the Aging Face and Body: A Thing of the Past? Dermatologic Surgery, 2016. 42 Supplement(2): p. S73-S76.
  43. Fabi, S.G., et al., Consensus Recommendations for Combined Aesthetic Interventions Using Botulinum Toxin, Fillers, and Microfocused Ultrasound in the Neck, Decolletage, Hands, and Other Areas of the Body. Dermatol Surg, 2016. 42(10): p. 1199-1208.
  44. Dressler, D., F. Adib Saberi, and H. Bigalke, Botulinum toxin therapy: reduction of injection site pain by pH normalisation. J Neural Transm (Vienna), 2016.
  45. Dayan, S.M.D., Combination Therapies: A Personal Perspective on the Practice Building Benefits. Dermatologic Surgery, 2016. 42 Supplement(2): p. S165-S167.
  46. Carruthers, J.M.D.F. and A.M.D.F. Carruthers, A Multimodal Approach to Rejuvenation of the Lower Face. Dermatologic Surgery, 2016. 42 Supplement(2): p. S89-S93.
  47. Carruthers, J., et al., Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices. Dermatol Surg, 2016. 42(5): p. 586-97.
  48. Bonaparte, J.P., et al., A Comparative Assessment of Three Formulations of Botulinum Toxin Type A for Facial Rhytides: A Systematic Review with Meta-Analyses. Plast Reconstr Surg, 2016. 137(4): p. 1125-40.
  49. Black, J.M.M.D., T.M.D. Pavicic, and D.H.M.D. Jones, Tempering Patient Expectations and Working With Budgetary Constraints When It Comes to a Single Versus a Multimodal Approach. Dermatologic Surgery, 2016. 42 Supplement(2): p. S161-S164.
  50. Alvarenga, A., et al., BOTOX-A injection of salivary glands for drooling. J Pediatr Surg, 2016.
  51. Yiannakopoulou, E., Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology, 2015. 95(1-2): p. 65-9.
  52. Wu, D.C., S.G. Fabi, and M.P. Goldman, Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck–Lower Face. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 76S-79S.
  53. Trevidic, P., J. Sykes, and G. Criollo-Lamilla, Anatomy of the Lower Face and Botulinum Toxin Injections. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 84S-91S.
  54. Sykes, J.M., et al., Newer Understanding of Specific Anatomic Targets in the Aging Face as Applied to Injectables: Facial Muscles–Identifying Optimal Targets for Neuromodulators. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 56S-61S.
  55. Rohrich, R.J., The “Soft-Tissue Fillers and Neuromodulators: International and Multidisciplinary Perspectives” Supplement. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 1S-3S.
  56. Ricci, L.H., et al., Ocular adverse effects after facial cosmetic procedures: a review of case reports. J Cosmet Dermatol, 2015.
  57. Punga, A.R., A. Eriksson, and M. Alimohammadi, Regional Diffusion of Botulinum Toxin in Facial Muscles: A Rando-mised Double-blind Study and a Consideration for Clinical Studies with Split-face Design. Acta Derm Venereol, 2015.
  58. Paracka, L., et al., Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures. J Neural Transm, 2015.
  59. Nahabet, E., J.E. Janis, and B. Guyuron, Neurotoxins: Expanding Uses of Neuromodulators in Medicine–Headache. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 104S-110S.
  60. Monheit, G., Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck–Upper Face (Glabella, Forehead, and Crow’s Feet). Plast Reconstr Surg, 2015. 136(5 Suppl): p. 72S-75S.
  61. Michaud, T., V. Gassia, and L. Belhaouari, Facial dynamics and emotional expressions in facial aging treatments. J Cosmet Dermatol, 2015. 14(1): p. 9-21.
  62. Levy, P.M., Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck–Jawline Contouring/Platysma Bands/Necklace Lines. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 80S-83S.
  63. Lee, H.H., et al., Effect of a Second Injection of Botulinum Toxin on Lower Facial Contouring, as Evaluated Using 3-Dimensional Laser Scanning. Dermatol Surg, 2015.
  64. Lam, S.M., R. Glasgold, and M. Glasgold, Analysis of Facial Aesthetics as Applied to Injectables. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 11S-21S.
  65. Kim, J.E., et al., The efficacy and safety of liquid-type botulinum toxin type a for the management of moderate to severe glabellar frown lines. Plast Reconstr Surg, 2015. 135(3): p. 732-41.
  66. Keaney, T., Male aesthetics. Skin Therapy Lett, 2015. 20(2): p. 5-7.
  67. Kang, A., E. Burns, and D.A. Glaser, Botulinum toxin A for palmar hyperhidrosis: associated pain, duration, and reasons for discontinuation of therapy. Dermatol Surg, 2015. 41(2): p. 297-8.
  68. Guerrrerosantos, J., et al., Effectiveness of botulinum toxin (type-a) administered by the fixed-site dosing approach versus the muscle area identification. Aesthetic Plast Surg, 2015. 39(2): p. 243-51.
  69. Alam, M., et al., Consensus statement regarding storage and reuse of previously reconstituted neuromodulators. Dermatol Surg, 2015. 41(3): p. 321-6.
  70. Schlessinger, J., et al., Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study. Dermatol Surg, 2014. 40(2): p. 176-83.
  71. Nayyar, P., et al., BOTOX: Broadening the Horizon of Dentistry. J Clin Diagn Res, 2014. 8(12): p. ZE25-9.
  72. Montaser-Kouhsari, L., et al., Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: a randomized, controlled trial. J Dermatolog Treat, 2014. 25(4): p. 337-41.
  73. Malcmacher, L., Botoxonomics. The economics of adding Botox and dermal fillers to your practice. J N J Dent Assoc, 2014. 85(4): p. 16-7.
  74. Lee, J.H., et al., Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. J Dermatolog Treat, 2014. 25(4): p. 326-30.
  75. Kouris, A., et al., Muscle weakness in treatment of palmar hyperhidrosis with botulinum toxin type a: can it be prevented? J Drugs Dermatol, 2014. 13(11): p. 1315-6.
  76. Kim, B.W., et al., Adverse events associated with botulinum toxin injection: a multidepartment, retrospective study of 5310 treatments administered to 1819 patients. J Dermatolog Treat, 2014. 25(4): p. 331-6.
  77. Jiang, H.Y., et al., Diffusion of two botulinum toxins type A on the forehead: double-blinded, randomized, controlled study. Dermatol Surg, 2014. 40(2): p. 184-92.
  78. Torrisi, B.M., et al., Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin. J Control Release, 2013. 165(2): p. 146-52.
  79. Sheen-Ophir, S. and Y. Almog, [Diplopia following subcutaneous injections of botulinum toxin for cosmetic or medical use]. Harefuah, 2013. 152(2): p. 98-100, 123, 122.
  80. Rzany, B., et al., Recommendations for the best possible use of botulinum neurotoxin type a (Speywood units) for aesthetic applications. J Drugs Dermatol, 2013. 12(1): p. 80-4.
  81. Ramirez-Castaneda, J., et al., Diffusion, spread, and migration of botulinum toxin. Mov Disord, 2013.
  82. Prager, W., Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines. Clin Pharmacol, 2013. 5: p. 39-52.
  83. Persaud, R., et al., An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep, 2013. 4(2): p. 10.
  84. Naumann, M., et al., Immunogenicity of botulinum toxins. J Neural Transm, 2013. 120(2): p. 275-90.
  85. Loyo, M. and T.C. Kontis, Cosmetic botulinum toxin: has it replaced more invasive facial procedures? Facial Plast Surg Clin North Am, 2013. 21(2): p. 285-98.
  86. Lee, S.H., et al., Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients. J Dermatolog Treat, 2013. 24(2): p. 133-6.
  87. Korman, J.B., H.R. Jalian, and M.M. Avram, Analysis of Botulinum Toxin Products and Litigation in the United States. Dermatol Surg, 2013.
  88. Kirby, J.S., C.N. Adgerson, and B.E. Anderson, A survey of dermatology resident education in cosmetic procedures. J Am Acad Dermatol, 2013. 68(2): p. e23-8.
  89. Kim, B.W., et al., Adverse events associated with botulinum toxin injection: A multidepartment, retrospective study of 5310 treatments administered to 1819 patients. J Dermatolog Treat, 2013.
  90. Khan, T.T., et al., Facial blanching due to neurotoxins: proposed mechanisms. Dermatol Surg, 2013. 39(1 Pt 1): p. 24-9.
  91. Kerscher, M., Y. Yutskovskaya, and T.C. Flynn, IncobotulinumtoxinA in esthetics. J Drugs Dermatol, 2013. 12(6): p. e111-20.
  92. Keaney, T.C. and T.S. Alster, Botulinum toxin in men: review of relevant anatomy and clinical trial data. Dermatol Surg, 2013. 39(10): p. 1434-43.
  93. Jones, D., Gentlemen, relax: commentary on botulinum toxin in men: a review of relevant anatomy and clinical trial data. Dermatol Surg, 2013. 39(10): p. 1444-5.
  94. Jandhyala, R., Improving consent procedures and evaluation of treatment success in cosmetic use of incobotulinumtoxinA: an assessment of the treat-to-goal approach. J Drugs Dermatol, 2013. 12(1): p. 72-8.
  95. Hexsel, D., et al., Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines. Dermatol Surg, 2013. 39(7): p. 1088-96.
  96. Hanke, C.W., et al., A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg, 2013. 39(6): p. 891-9.
  97. Hamilton, H.K. and K.A. Arndt, When is “too early” too early to start cosmetic procedures? JAMA Dermatol, 2013. 149(11): p. 1271.
  98. Gu, S. and R. Jin, Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol, 2013. 364: p. 21-44.
  99. Finzi, E., Antidepressant effects of botulinum toxin A: scientific rationale. J Psychiatry Neurosci, 2013. 38(5): p. E29.
  100. Cigna, E., et al., The use of botulinum toxin in the treatment of plunging nose: cosmetic results and a functional serendipity. Clin Ter, 2013. 164(2): p. e107-13.
  101. Chen, J.J. and K. Dashtipour, Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. Pharmacotherapy, 2013. 33(3): p. 304-18.
  102. Carruthers, J., et al., The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine–a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatol Surg, 2013. 39(3 Pt 2): p. 510-25.
  103. Carruthers, A., et al., The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine–a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice. Dermatol Surg, 2013. 39(3 Pt 2): p. 493-509.
  104. Bryant, A.M., et al., Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain. Protein J, 2013. 32(2): p. 106-17.
  105. Bonaparte, J.P., et al., A comparative assessment of three formulations of botulinum toxin A for facial rhytides: a systematic review and meta-analyses. Syst Rev, 2013. 2: p. 40.
  106. Banegas, R.A., et al., The South American Glabellar Experience Study (SAGE): A Multicenter Retrospective Analysis of Real-World Treatment Patterns Following the Introduction of IncobotulinumtoxinA in Argentina. Aesthet Surg J, 2013.
  107. Alimohammadi, M., M. Andersson, and A.R. Punga, Correlation of Botulinum Toxin Dose with Neurophysiological Parameters of Efficacy and Safety in the Glabellar Muscles: A Double-blind, Placebo-controlled, Randomized Study. Acta Derm Venereol, 2013.
  108. Alaraj, A.M., D.T. Oystreck, and T.M. Bosley, Variable ptosis after botulinum toxin type a injection with positive ice test mimicking ocular myasthenia gravis. J Neuroophthalmol, 2013. 33(2): p. 169-71.
  109. Al Hamdan, E.M., et al., Knowledge and attitude of dentists towards the use of botulinum toxin and dermal fillers in dentistry, Riyadh, Saudi Arabia. J Cosmet Laser Ther, 2013. 15(1): p. 46-54.
  110. Ahn, C.S., et al., Cosmetic Procedures Performed in the United States: A 16-Year Analysis. Dermatol Surg, 2013.
  111. Yu, K.C., et al., Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg, 2012. 14(3): p. 198-204.
  112. Yamauchi, P.S., Soft tissue filler and botulinum toxin treatment techniques. G Ital Dermatol Venereol, 2012. 147(1): p. 29-44.
  113. Thomas, M.K., J.A. D’Silva, and A.J. Borole, Facial sculpting: Comprehensive approach for aesthetic correction of round face. Indian J Plast Surg, 2012. 45(1): p. 122-7.
  114. Taylor, S.C., et al., AbobotulinumtoxinA for reduction of glabellar lines in patients with skin of color: post hoc analysis of pooled clinical trial data. Dermatol Surg, 2012. 38(11): p. 1804-11.
  115. Schulte, D., The Michigan Board of Dentistry’s Botox Statement: what does it mean? J Mich Dent Assoc, 2012. 94(5): p. 20-1.
  116. Pontes, H.A., et al., Uncommon foreign body reaction caused by botulinum toxin. J Craniofac Surg, 2012. 23(4): p. e303-5.
  117. Pickett, A., Inability of speculation to explain dose effect differences between botulinum toxin products. Arch Facial Plast Surg, 2012. 14(6): p. 467-8.
  118. Pellett, S., Learning from the past: historical aspects of bacterial toxins as pharmaceuticals. Curr Opin Microbiol, 2012. 15(3): p. 292-9.
  119. Pearlman, S.J., et al., Physician confidence in fillers and neurotoxins: a national survey. Arch Facial Plast Surg, 2012. 14(1): p. 67-8.
  120. Park, D.H., et al., Analysis of the patterns of lateral canthal rhytids and reference for botulinum toxin treatment in orientals. Aesthetic Plast Surg, 2012. 36(5): p. 1211-5.
  121. Nguyen, A.T., et al., Cosmetic medicine: facial resurfacing and injectables. Plast Reconstr Surg, 2012. 129(1): p. 142e-153e.
  122. Nettar, K. and C. Maas, Facial filler and neurotoxin complications. Facial Plast Surg, 2012. 28(3): p. 288-93.
  123. Moers-Carpi, M., et al., A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. J Cosmet Laser Ther, 2012. 14(6): p. 296-303.
  124. Marinelli, C., Comments on state’s botox statement. J Mich Dent Assoc, 2012. 94(7): p. 10.
  125. Maas, C., et al., Current aesthetic use of abobotulinumtoxinA in clinical practice: an evidence-based consensus review. Aesthet Surg J, 2012. 32(1 Suppl): p. 8S-29S.
  126. Luebberding, S. and M. Alexiades-Armenakas, Safety of dermal fillers. J Drugs Dermatol, 2012. 11(9): p. 1053-8.
  127. Lewis, M.B., Exploring the positive and negative implications of facial feedback. Emotion, 2012. 12(4): p. 852-9.
  128. Levy, L.L. and J.J. Emer, Complications of minimally invasive cosmetic procedures: prevention and management. J Cutan Aesthet Surg, 2012. 5(2): p. 121-32.
  129. Lee, S.K., Multiple intradermal small bolus injection of botulinum toxin: the limit and the potentiality. J Cosmet Laser Ther, 2012. 14(6): p. 304-6.
  130. Koshy, J.C., et al., Effect of dietary zinc and phytase supplementation on botulinum toxin treatments. J Drugs Dermatol, 2012. 11(4): p. 507-12.
  131. Kerscher, M., et al., Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res, 2012. 304(2): p. 155-61.
  132. Katona, P., Botulinum toxin: therapeutic agent to cosmetic enhancement to lethal biothreat. Anaerobe, 2012. 18(2): p. 240-3.
  133. Kane, M.A., et al., Development and validation of a new clinically-meaningful rating scale for measuring lateral canthal line severity. Aesthet Surg J, 2012. 32(3): p. 275-85.
  134. Jung, C.H., et al., A botulinum neurotoxin-like function of Potentilla chinensis extract that inhibits neuronal SNARE complex formation, membrane fusion, neuroexocytosis, and muscle contraction. Pharm Biol, 2012. 50(9): p. 1157-67.
  135. Jandhyala, R., Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence. J Drugs Dermatol, 2012. 11(6): p. 731-6.
  136. Jandhyala, R., Effectiveness of type A botulinum toxins for aesthetic indications and their relative economic impact. J Plast Reconstr Aesthet Surg, 2012. 65(6): p. 720-31.
  137. Jablonka, E.M., D.A. Sherris, and H.G. Gassner, Botulinum toxin to minimize facial scarring. Facial Plast Surg, 2012. 28(5): p. 525-35.
  138. Isaac, C.R., M.R. Chalita, and L.D. Pinto, Botox(R) after Botox(R) – a new approach to treat diplopia secondary to cosmetic botulinic toxin use: case reports. Arq Bras Oftalmol, 2012. 75(3): p. 213-4.
  139. Glogau, R., et al., OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines. Dermatol Surg, 2012. 38(11): p. 1794-803.
  140. Fukamizu, H., et al., Development of a three-microneedle device for hypodermic drug delivery and clinical application. Plast Reconstr Surg, 2012. 130(2): p. 451-5.
  141. Flynn, T.C., Advances in the use of botulinum neurotoxins in facial esthetics. J Cosmet Dermatol, 2012. 11(1): p. 42-50.
  142. Fernandez-Salas, E., et al., Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One, 2012. 7(11): p. e49516.
  143. Conkling, N., et al., Subjective rating of cosmetic treatment with botulinum toxin type A: do existing measures demonstrate interobserver validity? Ann Plast Surg, 2012. 69(4): p. 350-5.
  144. Chen, S., Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel), 2012. 4(10): p. 913-39.
  145. Casas, L.A., Introduction to: current aesthetic use of abobotulinumtoxinA in clinical practice: an evidence-based consensus review. Aesthet Surg J, 2012. 32(1 Suppl): p. 7S.
  146. Brun, C. and J.G. Brock-Utne, Paralyzed by beauty. J Clin Anesth, 2012. 24(1): p. 77-8.
  147. Blugerman, G., D. Schavelzon, and J. Alvarez, Near-infrared imaging of veins in facial injection of botulinum toxin and hyaluronic acid. Dermatol Surg, 2012. 38(7 Pt 2): p. 1252-3.
  148. Berry, M.G. and J.J. Stanek, Botulinum neurotoxin A: a review. J Plast Reconstr Aesthet Surg, 2012. 65(10): p. 1283-91.
  149. Berros, P., et al., Oculofacial contour asymmetries: Management of combined treatment with hyalurostructure and botulinum toxin injections. J Cosmet Laser Ther, 2012. 14(2): p. 111-6.
  150. Benecke, R., Clinical relevance of botulinum toxin immunogenicity. BioDrugs, 2012. 26(2): p. e1-9.

update: June 2017

Hyaluronic acid fillers
  1. Wollina, U. and A. Goldman, Botulinum toxin A and/or soft tissue fillers for facial rehabilitation. Wien Med Wochenschr, 2017. 167(3-4): p. 92-95.
  2. Suh, J.H., et al., A multicenter, randomized, double-blind clinical study to evaluate the efficacy and safety of a new monophasic hyaluronic acid filler with lidocaine 0.3% in the correction of nasolabial fold. J Cosmet Dermatol, 2017.
  3. Saththianathan, M., et al., The Role of Bacterial Biofilm in Adverse Soft-Tissue Filler Reactions: A Combined Laboratory and Clinical Study. Plast Reconstr Surg, 2017. 139(3): p. 613-621.
  4. Rzany, B., et al., An 18-Month Follow-up, Randomized Comparison of Effectiveness and Safety of Two Hyaluronic Acid Fillers for Treatment of Moderate Nasolabial Folds. Dermatol Surg, 2017. 43(1): p. 58-65.
  5. Prado, G. and J. Rodriguez-Feliz, Ocular Pain and Impending Blindness During Facial Cosmetic Injections: Is Your Office Prepared? Aesthetic Plast Surg, 2017. 41(1): p. 199-203.
  6. Ponzo, M.G., A. Carruthers, and S. Humphrey, Corrective Hyaluronic Acid Fillers and Combination Cosmetic Treatments for Facial Cutaneous Defects Due to Autoimmune Connective Tissue Diseases: A Retrospective Review. Dermatol Surg, 2017.
  7. Perez-Perez, L., et al., Delayed Adverse Subcutaneous Reaction to a New Family of Hyaluronic Acid Dermal Fillers With Clinical, Ultrasound, and Histologic Correlation. Dermatol Surg, 2017. 43(4): p. 605-608.
  8. Micheels, P., et al., Comparison of Two Swiss-Designed Hyaluronic Acid Gels: Six-Month Clinical Follow-Up. J Drugs Dermatol, 2017. 16(2): p. 154-161.
  9. Micheels, P., et al., Ultrasound and Histologic Examination after Subcutaneous Injection of Two Volumizing Hyaluronic Acid Fillers: A Preliminary Study. Plast Reconstr Surg Glob Open, 2017. 5(2): p. e1222.
  10. Micheels, P., S. Besse, and D. Sarazin, Two Crosslinking Technologies for Superficial Reticular Dermis Injection: A Comparative Ultrasound and Histologic Study. J Clin Aesthet Dermatol, 2017. 10(1): p. 29-36.
  11. Lin, C.H., et al., Filler migration to the forehead due to multiple filler injections in a patient addicted to cosmetic fillers. J Cosmet Laser Ther, 2017. 19(2): p. 124-126.
  12. Li, D., et al., Safety and Effectiveness of Juvederm Ultra Plus Injectable Gel in Correcting Severe Nasolabial Folds in Chinese Subjects. Plast Reconstr Surg Glob Open, 2017. 5(1): p. e1133.
  13. Lee, S. and M.T. Yen, Nonsurgical Rejuvenation of the Eyelids with Hyaluronic Acid Gel Injections. Semin Plast Surg, 2017. 31(1): p. 17-21.
  14. Lee, J.H., S.H. Kim, and E.S. Park, The Efficacy and Safety of HA IDF Plus (with Lidocaine) Versus HA IDF (Without Lidocaine) in Nasolabial Folds Injection: A Randomized, Multicenter, Double-Blind, Split-Face Study. Aesthetic Plast Surg, 2017. 41(2): p. 422-428.
  15. Jeong, K.H., et al., Efficacy and durability of hyaluronic acid fillers for malar enhancement: a prospective, randomized, spilt-face clinical controlled trial. J Cosmet Laser Ther, 2017.
  16. Hotta, T.A., The Expanding Market of Health Canada-Approved Hyaluronic Acid-Injectable Dermal Fillers. Plast Surg Nurs, 2017. 37(1): p. 25-31.
  17. Gandy, J., D. Bierman, and C. Zachary, Granulomatous reaction to Belotero Balance: A case study. J Cosmet Laser Ther, 2017: p. 1-3.
  18. Fallacara, A., et al., Hyaluronic Acid Fillers in Soft Tissue Regeneration. Facial Plast Surg, 2017. 33(1): p. 87-96.
  19. Fabbrocini, G., et al., Confocal microscopy and imaging profilometry: A new tool aimed to evaluate aesthetic procedures. J Cosmet Laser Ther, 2017. 19(1): p. 59-63.
  20. DeLorenzi, C., New High Dose Pulsed Hyaluronidase Protocol for Hyaluronic Acid Filler Vascular Adverse Events. Aesthet Surg J, 2017.
  21. Cheng, L., et al., Injectable Shape-Memorizing Three-Dimensional Hyaluronic Acid Cryogels for Skin Sculpting and Soft Tissue Reconstruction. Tissue Eng Part A, 2017. 23(5-6): p. 243-251.
  22. Calvisi, L., E. Gilbert, and D. Tonini, Rejuvenation of the perioral and lip regions with two new dermal fillers: The Italian experience with Vycross Technology. J Cosmet Laser Ther, 2017. 19(1): p. 54-58.
  23. Billon, R., B. Hersant, and J.P. Meningaud, [Hyaluronic acid rheology: Basics and clinical applications in facial rejuvenation]. Ann Chir Plast Esthet, 2017.
  24. Berguiga, M. and O. Galatoire, Tear trough rejuvenation: A safety evaluation of the treatment by a semi-cross-linked hyaluronic acid filler. Orbit, 2017. 36(1): p. 22-26.
  25. Ascher, B., et al., A 12-Month Follow-up, Randomized Comparison of Effectiveness and Safety of Two Hyaluronic Acid Fillers for Treatment of Severe Nasolabial Folds. Dermatol Surg, 2017. 43(3): p. 389-395.
  26. Al-Haddab, M., A. Abduljabbar, and A. Al-Somaily, The Sterility of Partially Used Hyaluronic Acid Fillers After Long Storage. Dermatol Surg, 2017.
  27. Zhu, Y., C. Crewe, and P.E. Scherer, Hyaluronan in adipose tissue: Beyond dermal filler and therapeutic carrier. Sci Transl Med, 2016. 8(323): p. 323ps4.
  28. Zhou, S.B., et al., A Randomized Clinical Trial of Comparing Monophasic Monodensified and Biphasic Nonanimal Stabilized Hyaluronic Acid Dermal Fillers in Treatment of Asian Nasolabial Folds. Dermatol Surg, 2016. 42(9): p. 1061-8.
  29. Zaleski-Larsen, L.A.D.O.F., et al., Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type. Dermatologic Surgery, 2016. 42 Supplement(2): p. S139-S149.
  30. Zaleski-Larsen, L.A., et al., Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type. Dermatol Surg, 2016. 42 Suppl 2: p. S139-49.
  31. You, H.J., et al., Tracking and Increasing Viability of Topically Injected Fibroblasts Suspended in Hyaluronic Acid Filler. J Craniofac Surg, 2016. 27(2): p. 521-5.
  32. Wu, Y., et al., Safety and Effectiveness of Hyaluronic Acid Injectable Gel in Correcting Moderate Nasolabial Folds in Chinese Subjects. J Drugs Dermatol, 2016. 15(1): p. 70-6.
  33. Wu, Y., et al., Clinical comparison between two hyaluronic acid-derived fillers in the treatment of nasolabial folds in Chinese subjects: BioHyalux versus Restylane. Arch Dermatol Res, 2016. 308(3): p. 145-51.
  34. Wu, W.T., et al., Consensus on Current Injectable Treatment Strategies in the Asian Face. Aesthetic Plast Surg, 2016. 40(2): p. 202-14.
  35. Wu, D.C.M.D.P. and J.B.M.D. Green, Rejuvenation of the Aging Arm: Multimodal Combination Therapy for Optimal Results. Dermatologic Surgery, 2016. 42 Supplement(2): p. S119-S123.
  36. Wollina, U., Facial rejuvenation starts in the midface: three-dimensional volumetric facial rejuvenation has beneficial effects on nontreated neighboring esthetic units. J Cosmet Dermatol, 2016. 15(1): p. 82-8.
  37. Wilson, A.J., et al., Current Applications of Facial Volumization with Fillers. Plast Reconstr Surg, 2016. 137(5): p. 872e-89e.
  38. Weiss, M.M.D., et al., Leg Rejuvenation: A Combination Approach: A Review and Our Experience. Dermatologic Surgery, 2016. 42 Supplement(2): p. S131-S138.
  39. Vulpe, R., et al., Crosslinked hydrogels based on biological macromolecules with potential use in skin tissue engineering. Int J Biol Macromol, 2016. 84: p. 174-81.
  40. Vanaman, M.M.D., S.G.M.D.F.F. Fabi, and S.E.M.D. Cox, Neck Rejuvenation Using a Combination Approach: Our Experience and a Review of the Literature. Dermatologic Surgery, 2016. 42 Supplement(2): p. S94-S100.
  41. Vanaman, M., S.G. Fabi, and S.E. Cox, Neck Rejuvenation Using a Combination Approach: Our Experience and a Review of the Literature. Dermatol Surg, 2016. 42 Suppl 2: p. S94-S100.
  42. Vanaman, M., S.G. Fabi, and J. Carruthers, Complications in the Cosmetic Dermatology Patient: A Review and Our Experience (Part 1). Dermatol Surg, 2016. 42(1): p. 1-11.
  43. Vanaman, M., S.G. Fabi, and J. Carruthers, Complications in the Cosmetic Dermatology Patient: A Review and Our Experience (Part 2). Dermatol Surg, 2016. 42(1): p. 12-20.
  44. Vanaman, M., et al., Emerging Trends in Nonsurgical Female Genital Rejuvenation. Dermatol Surg, 2016. 42(9): p. 1019-29.
  45. Thomas, W.W., L. Bucky, and O. Friedman, Injectables in the Nose: Facts and Controversies. Facial Plast Surg Clin North Am, 2016. 24(3): p. 379-89.
  46. Tan, P., R. Malhotra, and S. Ali, Hyaluronic acid fillers and hyaluronidase use in regional eye blocks. Anaesthesia, 2016. 71(8): p. 988-9.
  47. Tamboli, D. and R. Mancini, Hyaluronic Acid Gel Injection for Multiple Eyelid Folds in Asian Eyelids: A Novel Approach. Ophthal Plast Reconstr Surg, 2016.
  48. Sundaram, H., et al., Global Aesthetics Consensus: Botulinum Toxin Type A-Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg, 2016. 137(3): p. 518e-29e.
  49. Sundaram, H., et al., Pilot Comparative Study of the Topical Action of a Novel, Crosslinked Resilient Hyaluronic Acid on Skin Hydration and Barrier Function in a Dynamic, Three-Dimensional Human Explant Model. J Drugs Dermatol, 2016. 15(4): p. 434-41.
  50. Sundaram, H., et al., Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A-Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations. Plast Reconstr Surg, 2016. 137(5): p. 1410-23.
  51. Signorini, M., et al., Global Aesthetics Consensus: Avoidance and Management of Complications from Hyaluronic Acid Fillers-Evidence- and Opinion-Based Review and Consensus Recommendations. Plast Reconstr Surg, 2016. 137(6): p. 961e-71e.
  52. Seok, J., et al., A potential relationship between skin hydration and stamp-type microneedle intradermal hyaluronic acid injection in middle-aged male face. J Cosmet Dermatol, 2016. 15(4): p. 578-582.
  53. Scotti, L., et al., Recent Advancement in Natural Hyaluronidase Inhibitors. Curr Top Med Chem, 2016.
  54. Scherer, M.A., Specific aspects of a combined approach to male face correction: botulinum toxin A and volumetric fillers. J Cosmet Dermatol, 2016. 15(4): p. 566-574.
  55. Sahawatwong, S., et al., A Novel Technique of Supra Superficial Musculoaponeurotic System Hyaluronic Acid Injection for Lower Face Lifting. J Clin Aesthet Dermatol, 2016. 9(2): p. 58-62.
  56. Romeo, F., Upper Eyelid Filling With or Without Surgical Treatment. Aesthetic Plast Surg, 2016. 40(2): p. 223-35.
  57. Roh, N.K., et al., A Split-Face Study of the Effects of a Stabilized Hyaluronic Acid-Based Gel of Nonanimal Origin for Facial Skin Rejuvenation Using a Stamp-Type Multineedle Injector: A Randomized Clinical Trial. Plast Reconstr Surg, 2016. 137(3): p. 809-16.
  58. Rivkin, A.Z., Volume correction in the aging hand: role of dermal fillers. Clin Cosmet Investig Dermatol, 2016. 9: p. 225-32.
  59. Prasetyo, A.D., et al., Hyaluronic acid fillers with cohesive polydensified matrix for soft-tissue augmentation and rejuvenation: a literature review. Clin Cosmet Investig Dermatol, 2016. 9: p. 257-80.
  60. Pimentel de Miranda, A., N. Nassiri, and R.A. Goldberg, Engorgement of the Angular and Temporal Veins Following Periorbital Hyaluronic Acid Gel Injection. Ophthal Plast Reconstr Surg, 2016. 32(2): p. 123-6.
  61. Peterson, J.D.M.D. and S.L.M.D. Kilmer, Three-Dimensional Rejuvenation of the Decolletage. Dermatologic Surgery, 2016. 42 Supplement(2): p. S101-S107.
  62. Or, L., et al., Xanthelasma-Like Reaction to Filler Injection. Ophthal Plast Reconstr Surg, 2016.
  63. Noh, T.K., et al., Effects of highly concentrated hyaluronic acid filler on nasolabial fold correction: A 24-month extension study. J Dermatolog Treat, 2016. 27(6): p. 510-514.
  64. Nisi, G., et al., Carbon dioxide therapy and hyaluronic acid for cosmetic correction of the nasolabial folds. J Cosmet Dermatol, 2016. 15(2): p. 169-75.
  65. Narurkar, V.A.M.D., et al., A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study. Dermatologic Surgery, 2016. 42 Supplement(2): p. S177-S191.
  66. Narurkar, V.A., et al., Rejuvenating Hydrator: Restoring Epidermal Hyaluronic Acid Homeostasis With Instant Benefits. J Drugs Dermatol, 2016. 15(1): p. s24-37.
  67. Micheels, P., et al., Quantifying Depth of Injection of Hyaluronic Acid in the Dermis: Data from Clinical, Laboratory, and Ultrasound Settings. J Drugs Dermatol, 2016. 15(4): p. 483-90.
  68. Mannino, G.N. and S.R. Lipner, Current concepts in lip augmentation. Cutis, 2016. 98(5): p. 325-329.
  69. Manfredi, P.R., et al., [Techniques to enhance the accuracy and efficiency of injections of the face in aesthetic medicine]. Rev Stomatol Chir Maxillofac Chir Orale, 2016. 117(1): p. 46-50.
  70. Loh, K.T., et al., Prevention and management of vision loss relating to facial filler injections. Singapore Med J, 2016. 57(8): p. 438-43.
  71. Liew, S., et al., Consensus on Changing Trends, Attitudes, and Concepts of Asian Beauty. Aesthetic Plast Surg, 2016. 40(2): p. 193-201.
  72. Li, K.T., et al., Delayed-onset cerebral infarction after cosmetic facial injection using hyaluronic acid. J Formos Med Assoc, 2016.
  73. Leonidas, P., et al., Intravenous Hyaluronidase with Urokinase as Treatment for Arterial Hyaluronic Acid Embolism. Plast Reconstr Surg, 2016.
  74. Langelier, N.M.D., K.M.D. Beleznay, and J.M.D. Woodward, Rejuvenation of the Upper Face and Periocular Region: Combining Neuromodulator, Facial Filler, Laser, Light, and Energy-Based Therapies for Optimal Results. Dermatologic Surgery, 2016. 42 Supplement(2): p. S77-S82.
  75. Lacoste, C., et al., [Use of hyaluronidase to correct hyaluronic acid injections in aesthetic medicine]. Rev Stomatol Chir Maxillofac Chir Orale, 2016. 117(2): p. 96-100.
  76. La Gatta, A., et al., Hyaluronan dermal fillers via crosslinking with 1,4-butandiol diglycidyl ether: Exploitation of heterogeneous reaction conditions. J Biomed Mater Res B Appl Biomater, 2016. 104(1): p. 9-18.
  77. La Gatta, A., et al., Biophysical and biological characterization of a new line of hyaluronan-based dermal fillers: A scientific rationale to specific clinical indications. Mater Sci Eng C Mater Biol Appl, 2016. 68: p. 565-72.
  78. Kuwahara, H. and R. Ogawa, Using a Vibration Device to Ease Pain During Facial Needling and Injection. Eplasty, 2016. 16: p. e9.
  79. Kuhne, U., et al., Safety and performance of cohesive polydensified matrix hyaluronic acid fillers with lidocaine in the clinical setting – an open-label, multicenter study. Clin Cosmet Investig Dermatol, 2016. 9: p. 373-381.
  80. Kucuker, I., et al., The Effect of Chemodenervation by Botulinum Neurotoxin on the Degradation of Hyaluronic Acid Fillers: An Experimental Study. Plast Reconstr Surg, 2016. 137(1): p. 109-13.
  81. Kim, B.W., et al., A Randomized, Evaluator-Blinded, Split-Face Comparison Study of the Efficacy and Safety of a Novel Mannitol Containing Monophasic Hyaluronic Acid Dermal Filler for the Treatment of Moderate to Severe Nasolabial Folds. Ann Dermatol, 2016. 28(3): p. 297-303.
  82. Kang, B.K., et al., Treatment of glabella skin necrosis following injection of hyaluronic acid filler using platelet-rich plasma. J Cosmet Laser Ther, 2016. 18(2): p. 111-2.
  83. Joo, H.J., et al., A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Lidocaine-Containing Monophasic Hyaluronic Acid Filler for Nasolabial Folds. Plast Reconstr Surg, 2016. 137(3): p. 799-808.
  84. Jeong, S.H., et al., Long-lasting and bioactive hyaluronic acid-hydroxyapatite composite hydrogels for injectable dermal fillers: Physical properties and in vivo durability. J Biomater Appl, 2016. 31(3): p. 464-74.
  85. Iannitti, T., et al., Experimental and Clinical Efficacy of Two Hyaluronic Acid-based Compounds of Different Cross-Linkage and Composition in the Rejuvenation of the Skin. Pharm Res, 2016. 33(12): p. 2879-2890.
  86. Hyun, M.Y., et al., Efficacy and Safety of Hyaluronic Acid with and without Radiofrequency for Forehead Augmentation: A Pilot Study Using Three-Dimensional Imaging Analysis. Ann Dermatol, 2016. 28(1): p. 107-9.
  87. Hwang, C.J., et al., Rethinking the Role of Nitroglycerin Ointment in Ischemic Vascular Filler Complications: An Animal Model With ICG Imaging. Ophthal Plast Reconstr Surg, 2016. 32(2): p. 118-22.
  88. Hwang, C.J., Periorbital Injectables: Understanding and Avoiding Complications. J Cutan Aesthet Surg, 2016. 9(2): p. 73-9.
  89. Humphrey, S.M.D.F.F., K.M.D.F.F. Beleznay, and R.M.D.F.F. Fitzgerald, Combination Therapy in Midfacial Rejuvenation. Dermatologic Surgery, 2016. 42 Supplement(2): p. S83-S88.
  90. Hu, X.Z., et al., Posterior Ciliary Artery Occlusion Caused by Hyaluronic Acid Injections Into the Forehead: A Case Report. Medicine (Baltimore), 2016. 95(11): p. e3124.
  91. Gutowski, K.A., Hyaluronic Acid Fillers: Science and Clinical Uses. Clin Plast Surg, 2016. 43(3): p. 489-96.
  92. Goodman, G.J. and A. Van Den Broek, The modified tower vertical filler technique for the treatment of post-acne scarring. Australas J Dermatol, 2016. 57(1): p. 19-23.
  93. Goodman, G.J. and M.D. Clague, A Rethink on Hyaluronidase Injection, Intraarterial Injection, and Blindness: Is There Another Option for Treatment of Retinal Artery Embolism Caused by Intraarterial Injection of Hyaluronic Acid? Dermatol Surg, 2016. 42(4): p. 547-9.
  94. Gavard Molliard, S., S. Albert, and K. Mondon, Key importance of compression properties in the biophysical characteristics of hyaluronic acid soft-tissue fillers. J Mech Behav Biomed Mater, 2016. 61: p. 290-8.
  95. Franca Wanick, F.B., et al., Skin Remodeling Using Hyaluronic Acid Filler Injections in Photo-Aged Faces. Dermatol Surg, 2016. 42(3): p. 352-9.
  96. Fischer, T.C., G. Sattler, and G.G. Gauglitz, Hyaluron Filler Containing Lidocaine on a CPM Basis for Lip Augmentation: Reports from Practical Experience. Facial Plast Surg, 2016. 32(3): p. 283-8.
  97. Fischer, T., G. Sattler, and G. Gauglitz, [Lidocaine-containing hyaluronic acid filler on a CPM(R) basis for lip augmentation : Experience from clinical practice]. Hautarzt, 2016. 67(6): p. 472-8.
  98. Fasola, E. and R. Gazzola, Labia Majora Augmentation with Hyaluronic Acid Filler: Technique and Results. Aesthet Surg J, 2016. 36(10): p. 1155-1163.
  99. Fabi, S.G.M.D., et al., Combining Microfocused Ultrasound With Botulinum Toxin and Temporary and Semi-Permanent Dermal Fillers: Safety and Current Use. Dermatologic Surgery, 2016. 42 Supplement(2): p. S168-S176.
  100. Fabi, S.G.M.D. and J.M.D. Carruthers, Single Modality Approach to Rejuvenate the Aging Face and Body: A Thing of the Past? Dermatologic Surgery, 2016. 42 Supplement(2): p. S73-S76.
  101. Fabi, S.G., et al., Consensus Recommendations for Combined Aesthetic Interventions Using Botulinum Toxin, Fillers, and Microfocused Ultrasound in the Neck, Decolletage, Hands, and Other Areas of the Body. Dermatol Surg, 2016. 42(10): p. 1199-1208.
  102. Eilers, R.E.J.M.D., et al., A Combination Approach to Surgical Scars. Dermatologic Surgery, 2016. 42 Supplement(2): p. S150-S156.
  103. Di Gregorio, C. and S. D’Arpa, Therapeutic Use of Hyaluronic Acid Fillers in the Treatment of Corticosteroid-Induced Skin and Subcutaneous Atrophy. Dermatol Surg, 2016. 42(11): p. 1307-1310.
  104. Del Campo, R. and S. Mandy, Commentary on a Randomized Clinical Trial of Comparing Monophasic Monodensified and Biphasic Nonanimal Stabilized Hyaluronic Acid Dermal Fillers in Treatment of Asian Nasolabial Folds. Dermatol Surg, 2016. 42(9): p. 1069-70.
  105. Dayan, S.M.D., Combination Therapies: A Personal Perspective on the Practice Building Benefits. Dermatologic Surgery, 2016. 42 Supplement(2): p. S165-S167.
  106. Danhof, R.S. and J.L. Cohen, A Combination Approach to Perioral Rejuvenation. J Drugs Dermatol, 2016. 15(1): p. 111-2.
  107. D’Aloiso, M.C., M. Senzolo, and B. Azzena, Efficacy and Safety of Cross-Linked Carboxymethylcellulose Filler for Rejuvenation of the Lower Face: A 6-Month Prospective Open-Label Study. Dermatol Surg, 2016. 42(2): p. 209-17.
  108. da Costa, A., et al., Durability of Three Different Types of Hyaluronic Acid Fillers in Skin: Are There Differences Among Biphasic, Monophasic Monodensified, and Monophasic Polydensified Products? Aesthet Surg J, 2016.
  109. Costa, C.R., et al., Advances and Refinement in Hyaluronic Acid Facial Fillers. Plast Reconstr Surg, 2016. 138(2): p. 233e-6e.
  110. Coleman, K.M.M.D. and J.M.D. Pozner, Combination Therapy for Rejuvenation of the Outer Thigh and Buttock: A Review and Our Experience. Dermatologic Surgery, 2016. 42 Supplement(2): p. S124-S130.
  111. Chiang, C., S. Zhou, and K. Liu, Intravenous Hyaluronidase with Urokinase as Treatment for Arterial Hyaluronic Acid Embolism. Plast Reconstr Surg, 2016. 137(1): p. 114-21.
  112. Chiang, C., S. Zhou, and K. Liu, Reply to letter: Intravenous Hyaluronidase with Urokinase as Treatment for Rabbit Retinal Artery Hyaluronic Acid Embolism. Plast Reconstr Surg, 2016.
  113. Chen, W., et al., Retinal Branch Artery Embolization Following Hyaluronic Acid Injection: A Case Report. Aesthet Surg J, 2016.
  114. Chen, Q., Y. Liu, and D. Fan, Serious Vascular Complications after Nonsurgical Rhinoplasty: A Case Report. Plast Reconstr Surg Glob Open, 2016. 4(4): p. e683.
  115. Chang, S.H., et al., External Compression Versus Intravascular Injection: A Mechanistic Animal Model of Filler-Induced Tissue Ischemia. Ophthal Plast Reconstr Surg, 2016. 32(4): p. 261-6.
  116. Carruthers, J.M.D.F. and A.M.D.F. Carruthers, A Multimodal Approach to Rejuvenation of the Lower Face. Dermatologic Surgery, 2016. 42 Supplement(2): p. S89-S93.
  117. Carruthers, J., et al., Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices. Dermatol Surg, 2016. 42(5): p. 586-97.
  118. Butterwick, K.M.D. and N.M.D. Sadick, Hand Rejuvenation Using a Combination Approach. Dermatologic Surgery, 2016. 42 Supplement(2): p. S108-S118.
  119. Buhren, B.A., et al., Hyaluronidase: from clinical applications to molecular and cellular mechanisms. Eur J Med Res, 2016. 21(1): p. 5.
  120. Black, J.M.M.D., T.M.D. Pavicic, and D.H.M.D. Jones, Tempering Patient Expectations and Working With Budgetary Constraints When It Comes to a Single Versus a Multimodal Approach. Dermatologic Surgery, 2016. 42 Supplement(2): p. S161-S164.
  121. Bertossi, D., et al., The facial grid analysis for filler injection: a cohort study of 300 patients. G Ital Dermatol Venereol, 2016. 151(5): p. 467-72.
  122. Beer, K., Commentary on Skin Remodeling Using Hyaluronic Acid Filler Injections in Photo-Aged Faces. Dermatol Surg, 2016. 42(3): p. 360.
  123. Artzi, O., et al., Resistant and Recurrent Late Reaction to Hyaluronic Acid-Based Gel. Dermatol Surg, 2016. 42(1): p. 31-7.
  124. Andre, P. and E. Haneke, Nicolau syndrome due to hyaluronic acid injections. J Cosmet Laser Ther, 2016: p. 1-19.
  125. Notice of Retraction: Pak CS, et al. A Phase III, Randomized, Double-Blind, Matched-Pairs, Active-Controlled Clinical Trial and Preclinical Animal Study to Compare the Durability, Efficacy and Safety between Polynucleotide Filler and Hyaluronic Acid Filler in the Correction of Crow’s Feet: A New Concept of Regenerative Filler. J Korean Med Sci 2014; 29(Suppl 3): S201-S209. J Korean Med Sci, 2016. 31(2): p. 330.
  126. Yoo, K.H., et al., Efficacy of combination light-emitting diode (635 and 830 nm) therapy in treating local injection-site reactions after filler. Clin Exp Dermatol, 2015. 40(3): p. 333-5.
  127. Xi, W., Y. Zhang, and W. Su, The Hyaluronic Acid Injection in the Lower Eyelid Based on the Hooke’s Law. Plast Reconstr Surg, 2015. 136(4 Suppl): p. 101.
  128. Woodward, J., T. Khan, and J. Martin, Facial Filler Complications. Facial Plast Surg Clin North Am, 2015. 23(4): p. 447-58.
  129. Wong, C.H. and B. Mendelson, Newer Understanding of Specific Anatomic Targets in the Aging Face as Applied to Injectables: Aging Changes in the Craniofacial Skeleton and Facial Ligaments. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 44S-48S.
  130. Wollina, U., Midfacial rejuvenation by hyaluronic acid fillers and subcutaneous adipose tissue – A new concept. Med Hypotheses, 2015. 84(4): p. 327-30.
  131. Vanaman, M. and S.G. Fabi, Decolletage: Regional Approaches with Injectable Fillers. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 276s-281s.
  132. Talarico, S., et al., High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg, 2015. 41(12): p. 1361-9.
  133. Sykes, J.M., et al., Upper Face: Clinical Anatomy and Regional Approaches with Injectable Fillers. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 204s-218s.
  134. Surek, C., et al., Volumizing viaducts of the midface: defining the beut techniques. Aesthet Surg J, 2015. 35(2): p. 121-34.
  135. Sundaram, H., et al., Cohesivity of Hyaluronic Acid Fillers: Development and Clinical Implications of a Novel Assay, Pilot Validation with a Five-Point Grading Scale, and Evaluation of Six U.S. Food and Drug Administration-Approved Fillers. Plast Reconstr Surg, 2015. 136(4): p. 678-86.
  136. Sundaram, H. and S. Fagien, Cohesive Polydensified Matrix Hyaluronic Acid for Fine Lines. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 149s-163s.
  137. Sun, Z.S., et al., Clinical Outcomes of Impending Nasal Skin Necrosis Related to Nose and Nasolabial Fold Augmentation with Hyaluronic Acid Fillers. Plast Reconstr Surg, 2015. 136(4): p. 434e-41e.
  138. Souza Felix Bravo, B., et al., Delayed-type Necrosis after Soft-tissue Augmentation with Hyaluronic Acid. J Clin Aesthet Dermatol, 2015. 8(12): p. 42-7.
  139. Samuelson, U., et al., An Open-Label, Multicenter, Evaluator-Blinded Study to Assess the Efficacy and Safety of a New Hyaluronic Acid-Based Gel Product for Lip Enhancement. Dermatol Surg, 2015. 41(9): p. 1052-9.
  140. Salti, G. and R. Rauso, Facial Rejuvenation with Fillers: The Dual Plane Technique. J Cutan Aesthet Surg, 2015. 8(3): p. 127-33.
  141. Sadick, N.S., et al., The Facial Adipose System: Its Role in Facial Aging and Approaches to Volume Restoration. Dermatol Surg, 2015. 41 Suppl 1: p. S333-9.
  142. Rohrich, R.J., The “Soft-Tissue Fillers and Neuromodulators: International and Multidisciplinary Perspectives” Supplement. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 1S-3S.
  143. Riyaz, F.R. and D. Ozog, Hand rejuvenation. Semin Cutan Med Surg, 2015. 34(3): p. 147-52.
  144. Rho, N.K., et al., Consensus Recommendations for Optimal Augmentation of the Asian Face with Hyaluronic Acid and Calcium Hydroxylapatite Fillers. Plast Reconstr Surg, 2015. 136(5): p. 940-56.
  145. Raspaldo, H., et al., Lip and Perioral Enhancement: A 12-Month Prospective, Randomized, Controlled Study. J Drugs Dermatol, 2015. 14(12): p. 1444-52.
  146. Ramanadham, S.R. and R.J. Rohrich, Newer Understanding of Specific Anatomic Targets in the Aging Face as Applied to Injectables: Superficial and Deep Facial Fat Compartments–An Evolving Target for Site-Specific Facial Augmentation. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 49S-55S.
  147. Ohrlund, J.A. and K.L. Edsman, The Myth of the “Biphasic” Hyaluronic Acid Filler. Dermatol Surg, 2015. 41 Suppl 1: p. S358-64.
  148. Narins, R.S., M. Rubin, and S. Matarasso, Introduction for the Filler Special Issue. Dermatol Surg, 2015. 41 Suppl 1: p. S277.
  149. Moon du, G., T.I. Kwak, and J.J. Kim, Glans Penis Augmentation Using Hyaluronic Acid Gel as an Injectable Filler. World J Mens Health, 2015. 33(2): p. 50-61.
  150. Molina, B., et al., Patient Satisfaction and Efficacy of Full-Facial Rejuvenation Using a Combination of Botulinum Toxin Type A and Hyaluronic Acid Filler. Dermatol Surg, 2015. 41 Suppl 1: p. S325-32.

update: June 2017

Mesotherapy
  1. Sparavigna, A., B. Tenconi, and I. De Ponti, Antiaging, photoprotective, and brightening activity in biorevitalization: a new solution for aging skin. Clin Cosmet Investig Dermatol, 2015. 8: p. 57-65.
  2. Tedeschi, A., F. Lacarrubba, and G. Micali, Mesotherapy with an Intradermal Hyaluronic Acid Formulation for Skin Rejuvenation: An Intrapatient, Placebo-Controlled, Long-Term Trial Using High-Frequency Ultrasound. Aesthetic Plast Surg, 2014.
  3. Sezgin, B., et al., The Effect of Microneedle Thickness on Pain During Minimally Invasive Facial Procedures: A Clinical Study. Aesthet Surg J, 2014. 34(5): p. 757-765.
  4. Rodriguez-Gutierrez, G., et al., Nocardia brasiliensis infection: an emergent suppurative granuloma after mesotherapy. Int J Dermatol, 2014. 53(7): p. 888-90.
  5. Mammucari, M., et al., Role of the informed consent, from mesotherapy to opioid therapy. Eur Rev Med Pharmacol Sci, 2014. 18(4): p. 566-74.
  6. Iannitti, T., et al., Combination therapy of hyaluronic acid mesotherapic injections and sclerotherapy for treatment of lower leg telangiectasia without major venous insufficiency: a preliminary clinical study. Clin Appl Thromb Hemost, 2014. 20(3): p. 326-30.
  7. Gualdi, G., et al., Acute siliconomas of the face triggered by skin rejuvenation mesotherapy with low weight hyaluronic acid; surgical treatment and pathogenetic hypothesis. G Ital Dermatol Venereol, 2014.
  8. Bulam, H., et al., The Inhibitory Effect of Platelet-Rich Plasma on Botulinum Toxin Type-A: An Experimental Study in Rabbits. Aesthetic Plast Surg, 2014.
  9. Atkins, B.L. and T. Gottlieb, Skin and soft tissue infections caused by nontuberculous mycobacteria. Curr Opin Infect Dis, 2014. 27(2): p. 137-45.
  10. Zaragoza, J., et al., [A rare side effect of mesotherapy: Nicolau syndrome]. Ann Dermatol Venereol, 2013. 140(11): p. 713-7.
  11. Savoia, A., S. Landi, and A. Baldi, A new minimally invasive mesotherapy technique for facial rejuvenation. Dermatol Ther (Heidelb), 2013. 3(1): p. 83-93.
  12. Rodriguez-Gutierrez, G., et al., Nocardia brasiliensis infection: an emergent suppurative granuloma after mesotherapy. Int J Dermatol, 2013.
  13. Park, E.J., et al., Histological changes after treatment for localized fat deposits with phosphatidylcholine and sodium deoxycholate. J Cosmet Dermatol, 2013. 12(3): p. 240-3.
  14. Moftah, N., et al., Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol, 2013. 27(6): p. 686-93.
  15. Mammucari, M., et al., [Informed consent and experimental treatments: the case of mesotherapy]. Recenti Prog Med, 2013. 104(5): p. 214-7.
  16. Konda, D. and D.M. Thappa, Mesotherapy: What is new? Indian J Dermatol Venereol Leprol, 2013. 79(1): p. 127-34.
  17. Jayasinghe, S., et al., Mesotherapy for local fat reduction. Obes Rev, 2013.
  18. Baspeyras, M., et al., Clinical and biometrological efficacy of a hyaluronic acid-based mesotherapy product: a randomised controlled study. Arch Dermatol Res, 2013.
  19. Wassef, C. and B.K. Rao, The science of cellulite treatment and its long-term effectiveness. J Cosmet Laser Ther, 2012. 14(2): p. 50-8.
  20. Vukcevic, N.P., et al., Severe acute caffeine poisoning due to intradermal injections: mesotherapy hazard. Vojnosanit Pregl, 2012. 69(8): p. 707-13.
  21. Taieb, M., et al., Hyaluronic acid plus mannitol treatment for improved skin hydration and elasticity. J Cosmet Dermatol, 2012. 11(2): p. 87-92.
  22. Ramos-e-Silva, M., et al., Oleoma: rare complication of mesotherapy for cellulite. Int J Dermatol, 2012. 51(2): p. 162-7.
  23. Mammucari, M., et al., Role of mesotherapy in musculoskeletal pain: opinions from the italian society of mesotherapy. Evid Based Complement Alternat Med, 2012. 2012: p. 436959.
  24. Jager, C., et al., Bioactive reagents used in mesotherapy for skin rejuvenation in vivo induce diverse physiological processes in human skin fibroblasts in vitro- a pilot study. Exp Dermatol, 2012. 21(1): p. 72-5.
  25. El-Domyati, M., et al., Efficacy of mesotherapy in facial rejuvenation: a histological and immunohistochemical evaluation. Int J Dermatol, 2012. 51(8): p. 913-9.
  26. Wongkitisophon, P., et al., Cutaneous Mycobacterium abscessus Infection Associated with Mesotherapy Injection. Case Rep Dermatol, 2011. 3(1): p. 37-41.
  27. Tawfik, H.A., et al., Phosphatidylcholine for the treatment of prominent lower eyelid fat pads: a pilot study. Ophthal Plast Reconstr Surg, 2011. 27(3): p. 147-51.
  28. Sarkar, R., V.K. Garg, and V. Mysore, Position paper on mesotherapy. Indian J Dermatol Venereol Leprol, 2011. 77(2): p. 232-7.
  29. Ramos, A., et al., [Development of subcutaneous nodules after mesotherapy]. Enferm Infecc Microbiol Clin, 2011. 29(10): p. 775-7.
  30. Navarte, D.A. and J. Rosset-Llobet, Safety of subcutaneous microinjections (mesotherapy) in musicians. Med Probl Perform Art, 2011. 26(2): p. 79-83.
  31. Marrif, H.I., Thyroid hormones and mesotherapy. Front Endocrinol (Lausanne), 2011. 2: p. 5.
  32. Mammucari, M., et al., Mesotherapy, definition, rationale and clinical role: a consensus report from the Italian Society of Mesotherapy. Eur Rev Med Pharmacol Sci, 2011. 15(6): p. 682-94.
  33. Kutlubay, Z., Evaluation of mesotherapeutic injections of three different combinations of lipolytic agents for body contouring. J Cosmet Laser Ther, 2011. 13(4): p. 142-53.
  34. Herreros, F.O., A.M. Moraes, and P.E. Velho, Mesotherapy: a bibliographical review. An Bras Dermatol, 2011. 86(1): p. 96-101.
  35. Galmes-Truyols, A., et al., An outbreak of cutaneous infection due to Mycobacterium abscessus associated to mesotherapy. Enferm Infecc Microbiol Clin, 2011. 29(7): p. 510-4.
  36. Galadari, H. and F. Al Faresi, Mesotherapy. Skinmed, 2011. 9(6): p. 342-3.
  37. Duncan, D. and A.M. Rotunda, Injectable therapies for localized fat loss: state of the art. Clin Plast Surg, 2011. 38(3): p. 489-501, vii.
  38. Couderc, C., et al., [Non-tuberculous mycobacterial infections related to esthetic care in France, 2001-2010]. Med Mal Infect, 2011. 41(7): p. 379-83.
  39. Sivagnanam, G., Mesotherapy – The french connection. J Pharmacol Pharmacother, 2010. 1(1): p. 4-8.
  40. Schmutz, J.L., A. Barbaud, and P. Trechot, [Alopecia and mesotherapy]. Ann Dermatol Venereol, 2010. 137(4): p. 338.
  41. Rozhanets, A.R., E.A. Turova, and D.B. Kul’chitskaia, [Combined application of electric myo-stimulation and meso-therapy for the correction of age-related changes of the facial skin]. Vopr Kurortol Fizioter Lech Fiz Kult, 2010(4): p. 26-30.
  42. Rallis, E., et al., Mesotherapy-induced urticaria. Dermatol Surg, 2010. 36(8): p. 1355-6.
  43. Quinones, C., et al., An outbreak of Mycobacterium fortuitum cutaneous infection associated with mesotherapy. J Eur Acad Dermatol Venereol, 2010. 24(5): p. 604-6.
  44. Orjuela, D., et al., Cutaneous tuberculosis after mesotherapy: report of six cases. Biomedica, 2010. 30(3): p. 321-6.
  45. Mysore, V., Mesotherapy in Management of Hairloss – Is it of Any Use? Int J Trichology, 2010. 2(1): p. 45-6.
  46. Kim, J.B., et al., Ischemic colitis after mesotherapy combined with anti-obesity medications. World J Gastroenterol, 2010. 16(12): p. 1537-40.
  47. Hasegawa, T., T. Matsukura, and S. Ikeda, Mesotherapy for benign symmetric lipomatosis. Aesthetic Plast Surg, 2010. 34(2): p. 153-6.
  48. Gutierrez-de la Pena, J., et al., [Three cases of panniculitis due to Mycobacterium abscessus after mesotherapy]. Actas Dermosifiliogr, 2010. 101(2): p. 188-90.
  49. Da Mata Jardin, O., et al., [Follow-up on an outbreak in Venezuela of soft-tissue infection due to Mycobacterium abscessus associated with Mesotherapy]. Enferm Infecc Microbiol Clin, 2010. 28(9): p. 596-601.
  50. Correa, N.E., et al., Outbreak of mesotherapy-associated cutaneous infections caused by Mycobacterium chelonae in Colombia. Jpn J Infect Dis, 2010. 63(2): p. 143-5.
  51. Braccini, F. and D.M. Dohan Ehrenfest, [Advantages of combined therapies in cosmetic medicine for the treatment of face aging: botulinum toxin, fillers and mesotherapy]. Rev Laryngol Otol Rhinol (Bord), 2010. 131(2): p. 89-95.
  52. Babacan, T., et al., A case of the Behcet’s disease diagnosed by the panniculits after mesotherapy. Rheumatol Int, 2010. 30(12): p. 1657-9.
  53. Shaladi, A.M., et al., [Cervical lymphoadenopathy due to Pseudomonas aeruginosa following mesotherapy]. Infez Med, 2009. 17(3): p. 169-72.
  54. Regnier, S., et al., Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin Infect Dis, 2009. 49(9): p. 1358-64.
  55. Nabavi, C.B., D.S. Minckler, and J.P. Tao, Histologic features of mesotherapy-induced orbital fat inflammation. Ophthal Plast Reconstr Surg, 2009. 25(1): p. 69-70.
  56. Matarasso, A. and T.M. Pfeifer, Mesotherapy and injection lipolysis. Clin Plast Surg, 2009. 36(2): p. 181-92, v; discussion 193.
  57. Gokdemir, G., A. Kucukunal, and D. Sakiz, Cutaneous granulomatous reaction from mesotherapy. Dermatol Surg, 2009. 35(2): p. 291-3.
  58. Duque-Estrada, B., et al., Alopecia secondary to mesotherapy. J Am Acad Dermatol, 2009. 61(4): p. 707-9.
  59. Duncan, D., et al., Refinement of technique in injection lipolysis based on scientific studies and clinical evaluation. Clin Plast Surg, 2009. 36(2): p. 195-209, v-vi; discussion 211-3.
  60. Difonzo, E.M., et al., Mesotherapy and cutaneous Mycobacterium fortuitum infection. Int J Dermatol, 2009. 48(6): p. 645-7.
  61. Del-Castillo, M., et al., Mesotherapy-associated outbreak caused by Mycobacterium immunogenum. Emerg Infect Dis, 2009. 15(2): p. 357-9.
  62. Carbonne, A., et al., Outbreak of nontuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. J Clin Microbiol, 2009. 47(6): p. 1961-4.
  63. Beer, K. and J. Waibel, Disfiguring scarring following mesotherapy-associated Mycobacterium cosmeticum infection. J Drugs Dermatol, 2009. 8(4): p.
    391-3.
  64. Wanner, M. and M. Avram, An evidence-based assessment of treatments for cellulite. J Drugs Dermatol, 2008. 7(4): p. 341-5.
  65. Viana-Niero, C., et al., Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol, 2008. 46(3): p. 850-5.
  66. Strahan, J.E., J.L. Cohen, and J.A. Chorny, Granuloma annulare as a complication of mesotherapy: a case report. Dermatol Surg, 2008. 34(6): p. 836-8.
  67. Park, S.H., et al., Effectiveness of mesotherapy on body contouring. Plast Reconstr Surg, 2008. 121(4): p. 179e-85e.
  68. Olivero-Rivera, L., Mesotherapy for body sculpting. European staple of reshaping gaining ground here. Adv Nurse Pract, 2008. 16(11): p. 30.
  69. Munayco, C.V., et al., Outbreak of persistent cutaneous abscesses due to Mycobacterium chelonae after mesotherapy sessions, Lima, Peru. Rev Saude Publica, 2008. 42(1): p. 146-9.
  70. Lacarrubba, F., et al., Mesotherapy for skin rejuvenation: assessment of the subepidermal low-echogenic band by ultrasound evaluation with cross-sectional B-mode scanning. Dermatol Ther, 2008. 21 Suppl 3: p. S1-5.
  71. Kadry, R., et al., Multifocal scalp abscess with subcutaneous fat necrosis and scarring alopecia as a complication of scalp mesotherapy. J Drugs Dermatol, 2008. 7(1): p. 72-3.
  72. Garcia-Navarro, X., et al., Mycobacterium abscessus infection secondary to mesotherapy. Clin Exp Dermatol, 2008. 33(5): p. 658-9.
  73. Davis, M.D., T.I. Wright, and J.M. Shehan, A complication of mesotherapy: noninfectious granulomatous panniculitis. Arch Dermatol, 2008. 144(6): p. 808-9.
  74. Danilovic, D.L., et al., Factitious thyrotoxicosis induced by mesotherapy: a case report. Thyroid, 2008. 18(6): p. 655-7.
  75. Caruso, M.K., et al., An evaluation of mesotherapy solutions for inducing lipolysis and treating cellulite. J Plast Reconstr Aesthet Surg, 2008. 61(11): p. 1321-4.
  76. Atiyeh, B.S., A.E. Ibrahim, and S.A. Dibo, Cosmetic mesotherapy: between scientific evidence, science fiction, and lucrative business. Aesthetic Plast Surg, 2008. 32(6): p. 842-9.
  77. Al-Khenaizan, S., Facial cutaneous ulcers following mesotherapy. Dermatol Surg, 2008. 34(6): p. 832-4; discussion 834-5.
  78. Mesotherapy: mycobacteriosis. Complementary medicine can induce adverse effects. Prescrire Int, 2008. 17(94): p. 67.
  79. Vedamurthy, M., Mesotherapy. Indian J Dermatol Venereol Leprol, 2007. 73(1): p. 60-2.
  80. Sanudo, A., et al., Nontuberculous mycobacteria infection after mesotherapy: preliminary report of 15 cases. Int J Dermatol, 2007. 46(6): p. 649-53.
  81. Gamo, R., et al., Sporotrichosis following mesotherapy for arthrosis. Acta Derm Venereol, 2007. 87(5): p. 430-1.
  82. Doerr, T.D., Lipoplasty of the face and neck. Curr Opin Otolaryngol Head Neck Surg, 2007. 15(4): p. 228-32.
  83. Demirkan, F., et al., Mesotherapy: can it be a cause of perforator flap failure? Plast Reconstr Surg, 2007. 119(3): p. 1137-8.
  84. Co, A.C., M.F. Abad-Casintahan, and A. Espinoza-Thaebtharm, Submental fat reduction by mesotherapy using phosphatidylcholine alone vs. phosphatidylcholine and organic silicium: a pilot study. J Cosmet Dermatol, 2007. 6(4): p. 250-7.
  85. Tan, J. and B. Rao, Mesotherapy-induced panniculitis treated with dapsone: case report and review of reported adverse effects of mesotherapy. J Cutan Med Surg, 2006. 10(2): p. 92-5.
  86. Stachowski, J., et al., Mesotherapy: cosmetic applications. Int J Pharm Compd, 2006. 10(5): p. 331-4.
  87. Rotunda, A.M. and M.S. Kolodney, Mesotherapy and phosphatidylcholine injections: historical clarification and review. Dermatol Surg, 2006. 32(4): p. 465-80.
  88. Rivera-Olivero, I.A., et al., [Soft-tissue infections due to non-tuberculous mycobacteria following mesotherapy. What is the price of beauty]. Enferm Infecc Microbiol Clin, 2006. 24(5): p. 302-6.
  89. Lim, E.C. and R.C. Seet, Botulinum toxin injections to reduce adiposity: possibility, or fat chance? Med Hypotheses, 2006. 67(5): p. 1086-9.
  90. Colon-Soto, M., R.A. Peredo, and L.M. Vila, Systemic lupus erythematosus after mesotherapy with acetyl-L-carnitine. J Clin Rheumatol, 2006. 12(5): p. 261-2.
  91. Brown, S.A., The science of mesotherapy: chemical anarchy. Aesthet Surg J, 2006. 26(1): p. 95-8.
  92. Amin, S.P., R.G. Phelps, and D.J. Goldberg, Mesotherapy for facial skin rejuvenation: a clinical, histologic, and electron microscopic evaluation. Dermatol Surg, 2006. 32(12): p. 1467-72.
  93. Rotunda, A.M., M.M. Avram, and A.S. Avram, Cellulite: Is there a role for injectables? J Cosmet Laser Ther, 2005. 7(3-4): p. 147-54.
  94. Rose, P.T. and M. Morgan, Histological changes associated with mesotherapy for fat dissolution. J Cosmet Laser Ther, 2005. 7(1): p. 17-9.
  95. Rohrich, R.J., Mesotherapy: what is it? Does it work? Plast Reconstr Surg, 2005. 115(5): p. 1425.
  96. Matarasso, A., T.M. Pfeifer, and D.C. Plastic Surgery Educational Foundation, Mesotherapy for body contouring. Plast Reconstr Surg, 2005. 115(5): p. 1420-4.
  97. Lee, D.P. and S.E. Chang, Subcutaneous nodules showing fat necrosis owing to mesotherapy. Dermatol Surg, 2005. 31(2): p. 250-1.
  98. Henry, F., C. Pierard-Franchimont, and G.E. Pierard, [Clinical case of the month. Atypical mycobacteria and mesotherapy]. Rev Med Liege, 2005. 60(1): p. 7-10.
  99. Centers for Disease, C. and Prevention, Outbreak of mesotherapy-associated skin reactions–District of Columbia area, January-February 2005. MMWR Morb Mortal Wkly Rep, 2005. 54(44): p. 1127-30.
  100. Brandao, C., et al., Abdominal haematoma–a mesotherapy complication. Acta Derm Venereol, 2005. 85(5): p. 446.
  101. Bessis, D., J.J. Guilhou, and B. Guillot, Localized urticaria pigmentosa triggered by mesotherapy. Dermatology, 2004. 209(4): p. 343-4.
  102. Marco-Bonnet, J., et al., [Mycobacterial bovis BCG cutaneous infections following mesotherapy: 2 cases]. Ann Dermatol Venereol, 2002. 129(5 Pt 1): p. 728-31.
  103. Rosina, P., et al., Psoriasis and side-effects of mesotherapy. Int J Dermatol, 2001. 40(9): p. 581-3.
  104. Nagore, E., et al., Cutaneous infection with Mycobacterium fortuitum after localized microinjections (mesotherapy) treated successfully with a triple drug regimen. Acta Derm Venereol, 2001. 81(4): p. 291-3.
  105. Tennstedt, D. and J.M. Lachapelle, [Cutaneous adverse effects of mesotherapy]. Ann Dermatol Venereol, 1997. 124(2): p. 192-6.
  106. Doutre, M.S. and C. Beylot, [Side effects of mesotherapy]. Therapie, 1997. 52(2): p. 93-6.
  107. Grojean, M.F. and L. Vaillant, [Lichenoid eruption caused by mesotherapy]. Ann Med Interne (Paris), 1995. 146(5): p. 365-6.

 

update: june 2015
Sculptra/New-Fill
  1. Friedmann, D.P., S.G. Fabi, and M.P. Goldman, Combination of intense pulsed light, Sculptra, and Ultherapy for treatment of the aging face. J Cosmet Dermatol, 2014. 13(2): p. 109-18.
  2. Duracinsky, M., et al., Safety of poly-L-lactic acid (New-Fill(R)) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis, 2014. 14: p. 474.
  3. Alessio, R., et al., European expert recommendations on the use of injectable poly-L-lactic acid for facial rejuvenation. J Drugs Dermatol, 2014. 13(9): p. 1057-66.
  4. Schuller-Petrovic, S., et al., Early granulomatous foreign body reactions to a novel alginate dermal filler: the system’s failure? J Eur Acad Dermatol Venereol, 2013. 27(1): p. 121-3.
  5. Rose, A.E. and D. Day, Esthetic rejuvenation of the temple. Clin Plast Surg, 2013. 40(1): p. 77-89.
  6. Pontius, A.T., S.R. Chaiet, and E.F. Williams, 3rd, Midface injectable fillers: have they replaced midface surgery? Facial Plast Surg Clin North Am, 2013. 21(2): p. 229-39.
  7. Kontis, T.C., Contemporary review of injectable facial fillers. JAMA Facial Plast Surg, 2013. 15(1): p. 58-64.
  8. Duracinsky, M., et al., A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use. BMC Infect Dis, 2013. 13: p. 92.
  9. Binder, W.J., K. Dhir, and J. Joseph, The role of fillers in facial implant surgery. Facial Plast Surg Clin North Am, 2013. 21(2): p. 201-11.
  10. Roberts, S.A. and B.P. Arthurs, Severe visual loss and orbital infarction following periorbital aesthetic poly-(L)-lactic acid (PLLA) injection. Ophthal Plast Reconstr Surg, 2012. 28(3): p. e68-70.
  11. Palm, M. and P. Chayavichitsilp, The “skinny”on Sculptra: a practical primer to volumization with poly-L-lactic acid. J Drugs Dermatol, 2012. 11(9): p. 1046-52.
  12. Nguyen, A.T., et al., Cosmetic medicine: facial resurfacing and injectables. Plast Reconstr Surg, 2012. 129(1): p. 142e-153e.
  13. Nelson, L. and K.J. Stewart, Psychological morbidity and facial volume in HIV lipodystrophy: quantification of treatment outcome. J Plast Reconstr Aesthet Surg, 2012. 65(4): p. 439-47.
  14. Guardiani, E. and S.P. Davison, Angioedema after treatment with injectable poly-L-lactic acid (sculptra). Plast Reconstr Surg, 2012. 129(1): p. 187e-189e.
  15. Glogau, R.G., Fillers: from the past to the future. Semin Cutan Med Surg, 2012. 31(2): p. 78-87.
  16. Dayan, S.H., D.A. Ellis, and M.L. Moran, Facial fillers: discussion and debate. Facial Plast Surg Clin North Am, 2012. 20(3): p. 245-64.
  17. Schierle, C.F. and L.A. Casas, Nonsurgical rejuvenation of the aging face with injectable poly-L-lactic acid for restoration of soft tissue volume. Aesthet Surg J, 2011. 31(1): p. 95-109.
  18. Olivier Masveyraud, F., [Facial rejuvenation using L-polylactic acid: about 298 successive cases]. Ann Chir Plast Esthet, 2011. 56(2): p. 120-7.
  19. Goldman, M.P., Cosmetic use of poly-L-lactic acid: my technique for success and minimizing complications. Dermatol Surg, 2011. 37(5): p. 688-93.
  20. Hamilton, T.K. and C.M. Burgess, Considerations for the use of injectable poly-L-lactic acid in people of color. J Drugs Dermatol, 2010. 9(5): p. 451-6.
  21. Sadick, N.S. and L. Palmisano, Case study involving use of injectable poly-L-lactic acid (PLLA) for acne scars. J Dermatolog Treat, 2009. 20(5): p. 302-7.
  22. Reszko, A.E., et al., Late-onset subcutaneous nodules after poly-L-lactic acid injection. Dermatol Surg, 2009. 35 Suppl 1: p. 380-4.
  23. Mest, D.R. and G.M. Humble, Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid. Aesthetic Plast Surg, 2009. 33(4): p. 654-6.
  24. Lowe, N.J., et al., Injectable poly-l-lactic acid: 3 years of aesthetic experience. Dermatol Surg, 2009. 35 Suppl 1: p. 344-9.
  25. Lacombe, V., Sculptra: a stimulatory filler. Facial Plast Surg, 2009. 25(2): p. 95-9.
  26. Fitzgerald, R. and D. Vleggaar, Using poly-L-lactic acid (PLLA) to mimic volume in multiple tissue layers. J Drugs Dermatol, 2009. 8(10 Suppl): p. s5-14.
  27. Cobb, C., Saving face. Strategies to fight father time. Adv Nurse Pract, 2009. 17(4): p. 39-43, 68.
  28. Azizzadeh, B., Late-onset infections and granuloma formation after facial polylactic acid (new-fill) injections in women who are heavy smokers. Plast Reconstr Surg, 2009. 124(1): p. 316-7; author reply 317-8.
  29. Thiery, G., et al., [Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy]. Rev Stomatol Chir Maxillofac, 2008. 109(2): p. 103-5.
  30. Schulman, M.R., J. Lipper, and R.A. Skolnik, Correction of chest wall deformity after implant-based breast reconstruction using poly-L-lactic acid (Sculptra). Breast J, 2008. 14(1): p. 92-6.
  31. Sarnoff, D.S., R. Saini, and R.H. Gotkin, Comparison of filling agents for lip augmentation. Aesthet Surg J, 2008. 28(5): p. 556-63.
  32. Salles, A.G., et al., Evaluation of the poly-L-lactic acid implant for treatment of the nasolabial fold: 3-year follow-up evaluation. Aesthetic Plast Surg, 2008. 32(5): p. 753-6.
  33. Narins, R.S., Minimizing adverse events associated with poly-L-lactic acid injection. Dermatol Surg, 2008. 34 Suppl 1: p. S100-4.
  34. Mole, B., [Long-lasting filling procedures]. Ann Dermatol Venereol, 2008. 135(1 Pt 2): p. 1S39-47.
  35. Lowe, N.J., Optimizing poly-L-lactic acid use. J Cosmet Laser Ther, 2008. 10(1): p. 43-6.
  36. Levy, R.M., K.P. Redbord, and C.W. Hanke, Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol, 2008. 59(6): p. 923-33.
  37. Hotta, T., Core curriculum for plastic surgical nursing: dermal fillers. Plast Surg Nurs, 2008. 28(3): p. 131-5.
  38. Hamilton, D.G., N. Gauthier, and B.F. Robertson, Late-onset, recurrent facial nodules associated with injection of poly-L-lactic acid. Dermatol Surg, 2008. 34(1): p. 123-6; discussion 126.
  39. Grimaldi, M., et al., Lipostructure technique in Romberg syndrome. J Craniofac Surg, 2008. 19(4): p. 1089-91.
  40. Goldan, O., et al., Late-onset infections and granuloma formation after facial polylactic acid (New-Fill) injections in women who are heavy smokers. Plast Reconstr Surg, 2008. 121(5): p. 336e-338e.
  41. Dinman, S., Sculptra use in HIV-associated lipodystrophy. Plast Surg Nurs, 2008. 28(1): p. 53-4.
  42. Busso, M., Soft tissue augmentation: nonsurgical approaches to treatment of the mid and lower facial regions. Dermatol Nurs, 2008. 20(3): p. 211-4, 217-9.
  43. Burgess, C.M., Treatment of facial asymmetry with poly-L-lactic Acid: a case study. Aesthetic Plast Surg, 2008. 32(3): p. 552-4.
  44. Stewart, D.B., et al., Management of visible granulomas following periorbital injection of poly-L-lactic Acid. Ophthal Plast Reconstr Surg, 2007. 23(4): p. 298-301.
  45. Piquet, M., et al., [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy]. Rev Stomatol Chir Maxillofac, 2007. 108(6): p. 496-504.
  46. Keni, S.P. and D.M. Sidle, Sculptra (injectable poly-L-lactic acid). Facial Plast Surg Clin North Am, 2007. 15(1): p. 91-7, vii.
  47. Kelly, P.E., Injectable success: from fillers to Botox. Facial Plast Surg, 2007. 23(1): p. 7-18; discussion 19-20.
  48. Heffelfinger, R.N., et al., A simplified approach to midface aging. Arch Facial Plast Surg, 2007. 9(1): p. 48-55.
  49. Davison, S.P., J. Timpone, Jr., and C.M. Hannan, Surgical algorithm for management of HIV lipodystrophy. Plast Reconstr Surg, 2007. 120(7): p. 1843-58.
  50. Clymer, M.A., Evolution in techniques: lip augmentation. Facial Plast Surg, 2007. 23(1): p. 21-6.
  51. Beer, K., A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring from acne or varicella. Dermatol Surg, 2007. 33 Suppl 2: p. S159-67.
  52. Apikian, M., S. Roberts, and G.J. Goodman, Adverse reactions to polylactic acid injections in the periorbital area. J Cosmet Dermatol, 2007. 6(2): p. 95-101.
  53. Wolfram, D., A. Tzankov, and H. Piza-Katzer, Surgery for foreign body reactions due to injectable fillers. Dermatology, 2006. 213(4): p. 300-4.
  54. Vleggaar, D., Poly-L-lactic acid: consultation on the injection techniques. J Eur Acad Dermatol Venereol, 2006. 20 Suppl 1: p. 17-21.
  55. Thioly-Bensoussan, D., A new option for volumetric restoration: poly-L-lactic acid. J Eur Acad Dermatol Venereol, 2006. 20 Suppl 1: p. 12-6.
  56. Shumaker, P.R., et al., Effect of monopolar radiofrequency treatment over soft-tissue fillers in an animal model: part 2. Lasers Surg Med, 2006. 38(3): p. 211-7.
  57. Sherman, R.N., Sculptra: the new three-dimensional filler. Clin Plast Surg, 2006. 33(4): p. 539-50.
  58. Ralston, J.P., J.E. Blume, and N.C. Zeitouni, Treatment of postoperative soft tissue loss with injectable poly-L-lactic acid. J Drugs Dermatol, 2006. 5(10): p. 1000-1.
  59. Lowe, N.J., Dispelling the myth: appropriate use of poly-L-lactic acid and clinical considerations. J Eur Acad Dermatol Venereol, 2006. 20 Suppl 1: p. 2-6.
  60. Lam, S.M., B. Azizzadeh, and M. Graivier, Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg, 2006. 118(3 Suppl): p. 55S-63S.
  61. Jones, J.K., Patient safety considerations regarding dermal filler injections. Plast Surg Nurs, 2006. 26(3): p. 156-63.
  62. Graivier, M., Wire subcision for complete release of depressions, subdermal attachments, and scars. Aesthet Surg J, 2006. 26(4): p. 387-94.
  63. El-Beyrouty, C., et al., Poly-L-lactic acid for facial lipoatrophy in HIV. Ann Pharmacother, 2006. 40(9): p. 1602-6.
  64. Downie, J.B., Esthetic considerations for ethnic skin. Semin Cutan Med Surg, 2006. 25(3): p. 158-62.
  65. Broder, K.W. and S.R. Cohen, An overview of permanent and semipermanent fillers. Plast Reconstr Surg, 2006. 118(3 Suppl): p. 7S-14S.
  66. Beer, K.R. and M.I. Rendon, Use of sculptra mark in esthetic rejuvenation. Semin Cutan Med Surg, 2006. 25(3): p. 127-31.
  67. Bauer, U. and D. Vleggaar, Response to “New-fill injections may induce late-onset foreign body granulomatous reaction”. Plast Reconstr Surg, 2006. 118(1): p. 265; author reply 265-6.
  68. Vleggaar, D., Facial volumetric correction with injectable poly-L-lactic acid. Dermatol Surg, 2005. 31(11 Pt 2): p. 1511-7; discussion 1517-8.
  69. Parada, M.B., et al., A histologic study of adverse effects of different cosmetic skin fillers. Skinmed, 2005. 4(6): p. 345-9.
  70. Moy, R.L. and E.F. Fincher, Poly-L-lactic acid for the aesthetic correction of facial volume loss. Aesthet Surg J, 2005. 25(6): p. 646-8.
  71. Lowe, N.J., C.A. Maxwell, and R. Patnaik, Adverse reactions to dermal fillers: review. Dermatol Surg, 2005. 31(11 Pt 2): p. 1616-25.
  72. Jones, D., HIV facial lipoatrophy: causes and treatment options. Dermatol Surg, 2005. 31(11 Pt 2): p. 1519-29; discussion 1529.
  73. James, J.S., Sculptra facial treatment: new physician locator. AIDS Treat News, 2005(410): p. 4.
  74. Hamilton, M.M. and T. Hobgood, Emerging trends and techniques in male aesthetic surgery. Facial Plast Surg, 2005. 21(4): p. 324-8.
  75. England, L.J., et al., Effects of monopolar radiofrequency treatment over soft-tissue fillers in an animal model. Lasers Surg Med, 2005. 37(5): p. 356-65.
  76. Engelhard, P., G. Humble, and D. Mest, Safety of Sculptra: a review of clinical trial data. J Cosmet Laser Ther, 2005. 7(3-4): p. 201-5.
  77. Dijkema, S.J., B. van der Lei, and R.E. Kibbelaar, New-fill injections may induce late-onset foreign body granulomatous reaction. Plast Reconstr Surg, 2005. 115(5): p. 76e-78e.
  78. Christensen, L., et al., Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg, 2005. 29(1): p. 34-48.
  79. Burgess, C.M. and R.M. Quiroga, Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol, 2005. 52(2): p. 233-9.
  80. Borelli, C., et al., Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol, 2005. 18(6): p. 273-8.
  81. Beljaards, R.C., K.P. de Roos, and F.G. Bruins, NewFill for skin augmentation: a new filler or failure? Dermatol Surg, 2005. 31(7 Pt 1): p. 772-6; discussion 776.
  82. Andre, P., et al., Adverse reactions to dermal fillers: a review of European experiences. J Cosmet Laser Ther, 2005. 7(3-4): p. 171-6.
  83. Zimmermann, U.S. and T.J. Clerici, The histological aspects of fillers complications. Semin Cutan Med Surg, 2004. 23(4): p. 241-50.
  84. Vochelle, D., The use of poly-L-lactic acid in the management of soft-tissue augmentation: a five-year experience. Semin Cutan Med Surg, 2004. 23(4): p. 223-6.
  85. Vleggaar, D. and U. Bauer, Facial enhancement and the European experience with Sculptra (poly-l-lactic acid). J Drugs Dermatol, 2004. 3(5): p. 542-7.
  86. Munk, B., Sculptra. Posit Aware, 2004. 15(6): p. 31-2.
  87. Moyle, G.J., et al., A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med, 2004. 5(2): p. 82-7.
  88. Lombardi, T., et al., Orofacial granulomas after injection of cosmetic fillers. Histopathologic and clinical study of 11 cases. J Oral Pathol Med, 2004. 33(2): p. 115-20.
  89. James, J.S., Sculptra (formerly New Fill) for facial wasting–where to find information on the patient-assistance program. AIDS Treat News, 2004(407-408): p. 5.
  90. Humble, G. and D. Mest, Soft tissue augmentation using sculptra. Facial Plast Surg, 2004. 20(2): p. 157-63.
  91. Huff, B., Approval of Sculptra recommended. GMHC Treat Issues, 2004. 18(3-4): p. 15.
  92. FDA approves lipoatrophy filler. AIDS Patient Care STDS, 2004. 18(6): p. 366.
  93. Valantin, M.A., et al., Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS, 2003. 17(17): p. 2471-7.
  94. Lemperle, G., V. Morhenn, and U. Charrier, Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg, 2003. 27(5): p. 354-66; discussion 367.
  95. Cheonis, N., New-Fill to treat facial wasting. BETA, 2002. 15(2): p. 10-5.
  96. Berry, J., New-Fill for an old face. Posit Aware, 2002. 13(3): p. 34-5.
  97. Berger, D.S., New-Fill on “hold” and open-label for T-20. Posit Aware, 2002. 13(1): p. 64-5.

 

update: june 2015

 

Radiesse
  1. Yutskovskaya, Y., E. Kogan, and E. Leshunov, A randomized, split-face, histomorphologic study comparing a volumetric calcium hydroxylapatite and a hyaluronic acid-based dermal filler. J Drugs Dermatol, 2014. 13(9): p. 1047-52.
  2. Owosho, A.A., et al., Orofacial dermal fillers: foreign body reactions, histopathologic features, and spectrometric studies. Oral Surg Oral Med Oral Pathol Oral Radiol, 2014. 117(5): p. 617-25.
  3. Lorenc, Z.P. and E. Daro-Kaftan, Optimizing facial rejuvenation outcomes by combining poly-L-lactic acid, hyaluronic acid, calcium hydroxylapatite, and neurotoxins: two case studies. J Drugs Dermatol, 2014. 13(2): p. 191-5.
  4. Lodder, W.L. and F.G. Dikkers, Comparison of voice outcome after vocal fold augmentation with fat or calcium hydroxylapatite. Laryngoscope, 2014.
  5. Horn, D.L., K. DeMarre, and S.R. Parikh, Interarytenoid sodium carboxymethylcellulose gel injection for management of pediatric aspiration. Ann Otol Rhinol Laryngol, 2014. 123(12): p. 852-8.
  6. Gilbert, E. and L. Calvisi, Midface and perioral volume restoration: a conversation between the US and Italy. J Drugs Dermatol, 2014. 13(1): p. 67-74.
  7. Freshwater, M.F., Was it really Radiesse or whose algorithm is better? J Plast Reconstr Aesthet Surg, 2014. 67(4): p. 569-70.
  8. El-Halaby, A. and M.V. Furtado Araujo, Unusual radiographic finding during routine periodontal maintenance: a case report. Tex Dent J, 2014. 131(4): p. 297-300.
  9. Devoto, M.H., et al., Reply re: “Calcium hydroxylapatite (Radiesse) for the correction of periorbital hollows, dark circles, and lower eyelid bags”. Ophthal Plast Reconstr Surg, 2014. 30(5): p. 440-1.
  10. Dallara, J.M., et al., Calcium hydroxylapatite for jawline rejuvenation: consensus recommendations. J Cosmet Dermatol, 2014. 13(1): p. 3-14.
  11. Burroughs, J.R., Re: “Calcium hydroxylapatite (Radiesse) for the correction of periorbital hollows, dark circles, and lower eyelid bags”. Ophthal Plast Reconstr Surg, 2014. 30(5): p. 440.
  12. Biesman, B., Re: “Calcium hydroxyl-apatite (Radiesse) for the correction of periorbital hollows, dark circles, and lower eyelid bags”. Ophthal Plast Reconstr Surg, 2014. 30(6): p. 529.
  13. Bernardini, F.P., et al., Reply re: “Calcium hydroxyl-apatite (Radiesse) for the correction of periorbital hollows, dark circles, and lower eyelid bags”. Ophthal Plast Reconstr Surg, 2014. 30(6): p. 529-30.
  14. Bernardini, F.P., et al., Calcium hydroxyl-apatite (Radiesse) for the correction of periorbital hollows, dark circles, and lower eyelid bags. Ophthal Plast Reconstr Surg, 2014. 30(1): p. 34-9.
  15. Beer, K.R., Safety and effectiveness of injection of calcium hydroxylapatite via blunt cannula compared to injection by needle for correction of nasolabial folds. J Cosmet Dermatol, 2014. 13(4): p. 288-96.
  16. Moulonguet, I., et al., Foreign body reaction to Radiesse: 2 cases. Am J Dermatopathol, 2013. 35(3): p. e37-40.
  17. Assi, Pope, and Kessler, Oral and maxillofacial pathology case of the month. Foreign body giant cell reaction to cosmetic filler material radiesse. Tex Dent J, 2013. 130(7): p. 582, 620-1.
  18. Vrcek, I.M., P. Malouf, and G.D. Gilliland, A novel solution for superficially placed calcium hydroxylapatite (Radiesse) in the inferior eyelid. Orbit, 2012. 31(6): p. 431-2.
  19. Daley, T., et al., Oral lesions associated with injected hydroxyapatite cosmetic filler. Oral Surg Oral Med Oral Pathol Oral Radiol, 2012. 114(1): p. 107-11.
  20. Buchanan, A.G., et al., Anterior filler displacement following injection of calcium hydroxylapatite gel (Radiesse) for anophthalmic orbital volume augmentation. Ophthal Plast Reconstr Surg, 2012. 28(5): p. 335-7.
  21. Vagefi, M.R., et al., Orbital augmentation with injectable calcium hydroxylapatite for correction of postenucleation/evisceration socket syndrome. Ophthal Plast Reconstr Surg, 2011. 27(2): p. 90-4.
  22. Alam, M., et al., Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions. J Am Acad Dermatol, 2011. 65(1): p. 92-6.
  23. Sundaram, H., et al., Comparison of the rheological properties of viscosity and elasticity in two categories of soft tissue fillers: calcium hydroxylapatite and hyaluronic acid. Dermatol Surg, 2010. 36 Suppl 3: p. 1859-65.
  24. Lizzul, P.F. and V.A. Narurkar, The role of calcium hydroxylapatite (Radiesse) in nonsurgical aesthetic rejuvenation. J Drugs Dermatol, 2010. 9(5): p. 446-50.
  25. Kimura, M., T. Mau, and R.W. Chan, Viscoelastic properties of phonosurgical biomaterials at phonatory frequencies. Laryngoscope, 2010. 120(4): p. 764-8.
  26. Gargasz, S.S. and M.C. Carbone, Hand rejuvenation using Radiesse. Plast Reconstr Surg, 2010. 125(6): p. 259e-60e.
  27. Bass, L.S., et al., Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J, 2010. 30(2): p. 235-8.
  28. Valiyaparambil, J., K. Rengasamy, and S.M. Mallya, An unusual soft tissue radiopacity–radiographic appearance of a dermal filler. Br Dent J, 2009. 207(5): p. 211-2.
  29. Siclovan, H.R. and J.A. Jomah, Injectable calcium hydroxylapatite for correction of nasal bridge deformities. Aesthetic Plast Surg, 2009. 33(4): p. 544-8.
  30. Ridenour, B. and T.C. Kontis, Injectable calcium hydroxylapatite microspheres (Radiesse). Facial Plast Surg, 2009. 25(2): p. 100-5.
  31. Fakhre, G.P., et al., An evaluation of calcium hydroxylapatite (Radiesse) for cosmetic nasolabial fold correction: a meta-analysis and patient centric outcomes study. Ann Plast Surg, 2009. 63(5): p. 486-9.
  32. Edelson, K.L., Hand recontouring with calcium hydroxylapatite (Radiesse). J Cosmet Dermatol, 2009. 8(1): p. 44-51.
  33. Busso, M., Calcium hydroxylapatite (Radiesse): safety, techniques and pain reduction. J Drugs Dermatol, 2009. 8(10 Suppl): p. s21-3.
  34. Bank, D.E., A novel approach to treatment of the aging hand with Radiesse. J Drugs Dermatol, 2009. 8(12): p. 1122-6.
  35. Tzikas, T.L., A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation. Dermatol Surg, 2008. 34 Suppl 1: p. S9-15.
  36. Sires, B., S. Laukaitis, and P. Whitehouse, Radiesse-induced herpes zoster. Ophthal Plast Reconstr Surg, 2008. 24(3): p. 218-9.
  37. Jacovella, P.F., Use of calcium hydroxylapatite (Radiesse) for facial augmentation. Clin Interv Aging, 2008. 3(1): p. 161-74.
  38. Carruthers, A., et al., Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg, 2008. 34 Suppl 1: p. S78-84.
  39. Vagefi, M.R., et al., Injectable calcium hydroxylapatite for orbital volume augmentation. Arch Facial Plast Surg, 2007. 9(6): p. 439-42.
  40. Stupak, H.D., et al., Calcium hydroxylapatite gel (Radiesse) injection for the correction of postrhinoplasty contour deficiencies and asymmetries. Arch Facial Plast Surg, 2007. 9(2): p. 130-6.
  41. Sankar, V. and H.S. McGuff, Foreign body reaction to calcium hydroxylapatite after lip augmentation. J Am Dent Assoc, 2007. 138(8): p. 1093-6.
  42. Sadick, N.S., B.E. Katz, and D. Roy, A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face. Dermatol Surg, 2007. 33 Suppl 2: p. S122-6; discussion S126-7.
  43. Moers-Carpi, M., et al., A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg, 2007. 33 Suppl 2: p. S144-51.
  44. Graivier, M.H., et al., Calcium hydroxylapatite (Radiesse) for correction of the mid- and lower face: consensus recommendations. Plast Reconstr Surg, 2007. 120(6 Suppl): p. 55S-66S.
  45. Comite, S., et al., Minimizing discomfort during the injection of Radiesse with the use of either local anesthetic or ice. Dermatol Online J, 2007. 13(3): p. 5.
  46. Caton, T., et al., Viscoelasticity of hyaluronan and nonhyaluronan based vocal fold injectables: implications for mucosal versus muscle use. Laryngoscope, 2007. 117(3): p. 516-21.
  47. Busso, M. and D. Applebaum, Hand augmentation with Radiesse (Calcium hydroxylapatite). Dermatol Ther, 2007. 20(6): p. 385-7.
  48. Beer, K.R., Radiesse nodule of the lips from a distant injection site: report of a case and consideration of etiology and management. J Drugs Dermatol, 2007. 6(8): p. 846-7.
  49. Ahn, M.S., Calcium hydroxylapatite: Radiesse. Facial Plast Surg Clin North Am, 2007. 15(1): p. 85-90, vii.
  50. Silvers, S.L., et al., Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg, 2006. 118(3 Suppl): p. 34S-45S.
  51. Roy, D., N. Sadick, and D. Mangat, Clinical trial of a novel filler material for soft tissue augmentation of the face containing synthetic calcium hydroxylapatite microspheres. Dermatol Surg, 2006. 32(9): p. 1134-9.
  52. Jansen, D.A. and M.H. Graivier, Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg, 2006. 118(3 Suppl): p. 22S-30S, discussion 31S-33S.
  53. Jacovella, P.F., et al., Long-lasting results with hydroxylapatite (Radiesse) facial filler. Plast Reconstr Surg, 2006. 118(3 Suppl): p. 15S-21S.
  54. Jacovella, P.F., Calcium hydroxylapatite facial filler (Radiesse): indications, technique, and results. Clin Plast Surg, 2006. 33(4): p. 511-23.
  55. Godin, M.S., et al., Use of radiesse in combination with restylane for facial augmentation. Arch Facial Plast Surg, 2006. 8(2): p. 92-7.
  56. Berlin, A., J.L. Cohen, and D.J. Goldberg, Calcium hydroxylapatite for facial rejuvenation. Semin Cutan Med Surg, 2006. 25(3): p. 132-7.
  57. Evans, K.K., et al., The use of calcium hydroxylapatite for nipple projection after failed nipple-areolar reconstruction: early results. Ann Plast Surg, 2005. 55(1): p. 25-9; discussion 29.
  58. Comite, S.L., et al., Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol Online J, 2004. 10(2): p. 2.

 

update: june 2015

 

 

 

 

 

 

 

Platelet Rich Plasma (PRP)

PRP 2016 met abstracts

  1. Arora, S., et al., Quantification of platelets and platelet derived growth factors from platelet-rich-plasma (PRP) prepared at different centrifugal force (g) and time. Transfus Apher Sci, 2016.
  2. Asif, M., S. Kanodia, and K. Singh, Combined autologous platelet-rich plasma with microneedling verses microneedling with distilled water in the treatment of atrophic acne scars: a concurrent split-face study. J Cosmet Dermatol, 2016.
  3. Bioulac, B., W. Heppt, and M. Heppt, [Transfer of autologous fat and plasma : The future of anti-aging medicine?]. HNO, 2015. 63(7): p. 497-503.
  4. Bulam, H., et al., The Inhibitory Effect of Platelet-Rich Plasma on Botulinum Toxin Type-A: An Experimental Study in Rabbits. Aesthetic Plast Surg, 2015. 39(1): p. 134-40.
  5. Centeno, C.J., et al., Is cosmetic platelet-rich plasma a drug to be regulated by the Food and Drug Administration? J Cosmet Dermatol, 2011. 10(3): p. 171-3.
  6. Cervelli, V., et al., The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: clinical and histomorphometric evaluation. Biomed Res Int, 2014. 2014: p. 760709.
  7. Cervelli, V., et al., Application of platelet-rich plasma in plastic surgery: clinical and in vitro evaluation. Tissue Eng Part C Methods, 2009. 15(4): p. 625-34.
  8. Cervelli, V., et al., Use of platelet-rich plasma and hyaluronic acid in the loss of substance with bone exposure. Adv Skin Wound Care, 2011. 24(4): p. 176-81.
  9. Chawla, S., Split Face Comparative Study of Microneedling with PRP Versus Microneedling with Vitamin C in Treating Atrophic Post Acne Scars. J Cutan Aesthet Surg, 2014. 7(4): p. 209-12.
  10. Cho, J.M., et al., Effect of platelet-rich plasma on ultraviolet b-induced skin wrinkles in nude mice. J Plast Reconstr Aesthet Surg, 2011. 64(2): p. e31-9.
  11. Cieslik-Bielecka, A., et al., L-PRP/L-PRF in esthetic plastic surgery, regenerative medicine of the skin and chronic wounds. Curr Pharm Biotechnol, 2012. 13(7): p. 1266-77.
  12. Fabi, S. and H. Sundaram, The potential of topical and injectable growth factors and cytokines for skin rejuvenation. Facial Plast Surg, 2014. 30(2): p. 157-71.
  13. Fukaya, M. and A. Ito, A New Economic Method for Preparing Platelet-rich Plasma. Plast Reconstr Surg Glob Open, 2014. 2(6): p. e162.
  14. Gentile, P., et al., The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial. Stem Cells Transl Med, 2015. 4(11): p. 1317-23.
  15. Ibrahim, Z.A., et al., Comparison between the efficacy and safety of platelet-rich plasma vs. microdermabrasion in the treatment of striae distensae: clinical and histopathological study. J Cosmet Dermatol, 2015. 14(4): p. 336-46.
  16. Kawazoe, T. and H.H. Kim, Tissue augmentation by white blood cell-containing platelet-rich plasma. Cell Transplant, 2012. 21(2-3): p. 601-7.
  17. Kim, D.H., et al., Can Platelet-rich Plasma Be Used for Skin Rejuvenation? Evaluation of Effects of Platelet-rich Plasma on Human Dermal Fibroblast. Ann Dermatol, 2011. 23(4): p. 424-31.
  18. Kushida, S., et al., Effects of platelet-rich plasma on proliferation and myofibroblastic differentiation in human dermal fibroblasts. Ann Plast Surg, 2013. 71(2): p. 219-24.
  19. Lee, S.H., et al., Therapeutic efficacy of autologous platelet-rich plasma and polydeoxyribonucleotide on female pattern hair loss. Wound Repair Regen, 2015. 23(1): p. 30-6.
  20. Leo, M.S., et al., Systematic review of the use of platelet-rich plasma in aesthetic dermatology. J Cosmet Dermatol, 2015. 14(4): p. 315-23.
  21. Li, Z.J., et al., Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg, 2012. 38(7 Pt 1): p. 1040-6.
  22. Lubkowska, A., B. Dolegowska, and G. Banfi, Growth factor content in PRP and their applicability in medicine. J Biol Regul Homeost Agents, 2012. 26(2 Suppl 1): p. 3S-22S.
  23. Mehryan, P., et al., Assessment of efficacy of platelet-rich plasma (PRP) on infraorbital dark circles and crow’s feet wrinkles. J Cosmet Dermatol, 2014. 13(1): p. 72-8.
  24. Miao, Y., et al., [Effect of PRP on the proliferation of dermal papilla cells and hair follicle regeneration in mice]. Zhonghua Zheng Xing Wai Ke Za Zhi, 2013. 29(2): p. 131-5.
  25. Miao, Y., et al., Promotional effect of platelet-rich plasma on hair follicle reconstitution in vivo. Dermatol Surg, 2013. 39(12): p. 1868-76.
  26. Pinto, J.M., et al., Application of platelet-rich plasma in the treatment of chronic skin ulcer – case report. An Bras Dermatol, 2014. 89(4): p. 638-40.
  27. Ramos-Torrecillas, J., et al., Clinical utility of growth factors and platelet-rich plasma in tissue regeneration: a review. Wounds, 2014. 26(7): p. 207-13.
  28. Redaelli, A., D. Romano, and A. Marciano, Face and neck revitalization with platelet-rich plasma (PRP): clinical outcome in a series of 23 consecutively treated patients. J Drugs Dermatol, 2010. 9(5): p. 466-72.
  29. Rigotti, G., et al., Expanded Stem Cells, Stromal-Vascular Fraction, and Platelet-Rich Plasma Enriched Fat: Comparing Results of Different Facial Rejuvenation Approaches in a Clinical Trial. Aesthet Surg J, 2016. 36(3): p. 261-70.
  30. Shin, M.K., et al., Platelet-rich plasma combined with fractional laser therapy for skin rejuvenation. Dermatol Surg, 2012. 38(4): p. 623-30.
  31. Venter, N.G., et al., Use of platelet-rich plasma in deep second- and third-degree burns. Burns, 2016.
  32. Willemsen, J.C., et al., The effects of platelet-rich plasma on recovery time and aesthetic outcome in facial rejuvenation: preliminary retrospective observations. Aesthetic Plast Surg, 2014. 38(5): p. 1057-63.
  33. Yuksel, E.P., et al., Evaluation of effects of platelet-rich plasma on human facial skin. J Cosmet Laser Ther, 2014. 16(5): p. 206-8.
  34. Zhu, J.T., et al., The efficacy of autologous platelet-rich plasma combined with erbium fractional laser therapy for facial acne scars or acne. Mol Med Rep, 2013. 8(1): p. 233-7.